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Over the last two decades there is burgeoning interest in neural stem/progenitor cells 
(NSCs) for both developmental research and cell-based therapeutic applications. 
Although functional properties of human NSCs, in terms of their tumor-homing, in 
vivo regenerative and in vitro differentiation capacities, have been extensively studied, 
the molecular mechanisms underlying their self-renewal and differentiation are 
incompletely, if not poorly, understood. Human embryonic stem cells (hESCs) offer a 
valuable source of NSCs to elucidate these mechanisms. Here, we derived NSCs 
from hESCs and further differentiated these hESC-derived NSCs into NG2+ glial 
progenitor cells (GPCs). PAX6 and SOX2 are two transcription factors that 
characterize NSCs, and function as key determinants of the human neuroectodermal 
fate that drive neurogenesis or self-renewal, respectively. Accordingly, we observed 
the downregulation of PAX6 and SOX2 expression in hESC-derived NSCs upon 
differentiation into GPCs. microRNAs (miRNAs) are negative regulators of gene 
expression that have reportedly been implicated in NSC self-renewal and fate 
commitment, and thus are plausibly involved in the downregulation of PAX6 and 
SOX2 in NSCs during differentiation towards the glial lineage. Utilizing miRNA 
microarrays, we have identified four miRNAs, miR-21, -22, -145 and -221, to be 
upregulated in GPCs compared with NSCs, among which miR-22 and miR-221 were 
demonstrated to be putative PAX6-targeting miRNAs. The ectopic expression of miR-
145 by baculoviral vectors repressed SOX2 protein expression in human NSCs, 
while inhibition of miR-145 using baculoviral decoy vectors induced the opposite. 
Thus, this study extends upon previous findings that miR-145 regulates SOX2 
expression in hESCs and glioma cells, and indicates that miR-145 modulates the 
transition from multipotency to fate commitment in NSCs. Together, this study 
demonstrates a facile approach to derive GPCs from NSCs and uncovers a 
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mechanistic role of miRNAs in regulating self-renewal and lineage specification in 
human NSCs by possibly acting on key fate determining transcription factors. 
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Chapter 1: Introduction 
1.1 Neural stem cells 
1.1.1 A brief history of NSCs 
The field of neural stem cell (NSC) biology has its humble beginnings in the second 
half of the 19th century. Several published observations at that time alluded to the 
existence of a population of actively dividing, multipotent cells that drive human brain 
development (Breunig et al., 2011). One such pioneering observation was by 
Wilhelm His (His, 1874, 1904). He noted the distinct localization of mitotically active 
cells near the surface of ventricles and not in the overlying cortical layers of the 
embryonic human brain, and formulated the concept that all neurons were derived 
from these germinal cells that propagate near the ventricular surface, a region now 
regarded as the subventricular zone (SVZ). Through most of the 20th century, the 
field was fraught with misunderstandings and its progress was hampered by the long-
held dogma of the immutability of adult brain tissue, largely due to a lack of evidence 
to the contrary with only a few isolated reports challenging this dogma (Altman, 1962; 
Altman and Das, 1965; Kaplan and Hinds, 1977). For example, Altman (1962) 
reported evidence for neurogenesis in the adult rat brain through the use of [3H]-
thymidine autoradiography, which traces proliferative cells in the brain, but these 
findings were met with skepticism during that period. It was only in the 1990s, starting 
with the isolation of NSCs from both fetal and adult brains of rodents (Reynolds et al., 
1992; Reynolds and Weiss, 1992) and followed by the isolation of human NSCs (Flax 
et al., 1998), that the existence of the NSC as a common progenitor for neurons, 
astrocytes and oligodendrocytes was accepted and the dogma was replaced by the 
concept of ongoing neurogenesis in specific regions of the adult brain. Since then, 
we have envisioned the possibility of novel strategies for the treatment of 
neurodegenerative diseases. Especially in the last two decades, there has been a 
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burgeoning interest in NSCs from both basic developmental and medical 
perspectives. 
 
1.1.2 The “definition” of an NSC 
The contemporary view of NSCs is not without its foibles. In principle, an NSC is 
functionally defined to be an uncommitted, multipotent cell with the capacity to self-
renew and generate the major cells of the central nervous system (CNS), i.e. 
neurons and glia (typically, astrocytes and oligodendrocytes). However, there is still 
inconsistency regarding the use of the term “neural stem cell”, and the numerous 
lineage mapping and genetic studies in recent years have given rise to a number of 
varied ways of characterizing and classifying NSCs and neural progenitors (Parker et 
al., 2005; Seaberg and van der Kooy, 2003). 
There are a number of problems that make distinguishing bona fide NSCs from their 
more lineage restricted progeny difficult. (i) The lack of a definitive marker or set of 
markers to specifically identify NSCs is one such problem. Though there are 
numerous reports of an extensive number of selection markers that allow for the 
distinction of NSCs from other neural or non-neural cells, none of the markers can 
exclusively identify NSCs as many are also found in more committed neural 
progenitors, differentiated cells or even in other cell types (Kaneko et al., 2000; 
Rietze et al., 2001; Uchida et al., 2000; Yuan et al., 2011). Furthermore, there are 
certain neural subtypes, such as radial glial cells, that display the multipotentiality of 
NSCs to differentiate into neurons and glia, but yet express markers of committed 
astroglial cells (Doetsch et al., 1999; Merkle et al., 2004). (ii) Another problem is 
caused by substantial differences between NSCs from different species. Though 
many features of NSC regulation and production are conserved across mammalian 
species, several cellular components and processes of brain development have 
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evolved in primates to increase neuronal production and give rise to larger 
neocortices (Smart et al., 2002). These species-specific differences raise challenges 
in translating studies characterizing NSCs in lower organisms to human NSCs, which 
have been found to bear unique intrinsic properties related to different spatial and 
temporal distribution (Breunig et al., 2011). (iii) A third problem is due to differences 
between embryonic NSCs and adult NSCs. There is evidence that NSCs alter their 
characteristics over the course of development. NSCs in the developing brain are 
believed to be actively proliferating, driving an initial wave of neurogenesis prior to 
gliogenesis, while, in contrast, NSCs in the adult brain adopt a more quiescent state. 
A study demonstrating that murine NSCs from early to mid-gestation generate more 
neurons than those from later stages when cultured in vitro suggests that this 
difference is plausibly cell-intrinsic rather than environmental (Qian et al., 2000). (iv) 
Lastly, differences among NSCs found in different regions of the CNS and NSCs 
cultured in vitro add to the ambiguity in determining a bona fide NSC identity. NSCs 
from different regions of the developing or adult brain have been found to express 
region-specific transcription factors that govern their self-renewal and cell-fate 
choices (Marin and Rubenstein, 2001; Schuurmans and Guillemot, 2002). 
Furthermore, they have a propensity to lose their in vivo positional identity when 
propagated and maintained in vitro. Several reports have found that the use of 
exogenous growth factors, such as basic fibroblast growth factor (bFGF), to maintain 
proliferation and ‘stemness’ of in vitro murine NSC cultures alters their intrinsic 
positional identity (Gabay et al., 2003; Hack et al., 2004; Santa-Olalla et al., 2003). 
Hack et al. (2004) reported that NSCs and neural progenitors from the dorsal or 
ventral embryonic mouse telencephalon when propagated in in vitro neurosphere 




Therefore, within the context of this thesis, for the sake of simplicity and to evade the 
NSC versus neural progenitor debate, the term “NSC” is mainly restricted to the 
description of cells bearing neuroectodermal identity with the cardinal features of self-
renewal and multipotency, i.e. the ability to give rise to glial and neuronal cells. 
 
1.1.3 NSCs in development and regenerative medicine 
With the isolation of mammalian NSCs, immense attention has been focused on 
NSCs as models and tools for developmental and therapeutic studies. NSCs have 
been instrumental in advancing our knowledge in developmental neurobiology. 
Myriad studies on the spatial and temporal organization of NSCs in vivo within the 
brains of rodents have shed light on the regulation of neurogenesis and fate 
specification of mammalian NSCs (Ming and Song, 2011). These studies have 
elucidated region-specific gene expression patterns in NSCs and progenitors, giving 
rise to knowledge of a compendium of transcription factors and genes that regulate 
self-renewal and influence lineage commitment decisions in NSCs. Studies on the 
NSC niche in specific regions of the CNS have also led to the discovery of several 
exogenous factors that regulate NSC function and differentiation that have been 
useful for improving in vitro culturing methods of NSCs (Alvarez-Buylla and Lim, 2004; 
Shen et al., 2004; Song et al., 2002). 
While animal models remain an important tool for translational research, inherent 
genetic and anatomical differences between rodents and man impairs the translation 
of insights from mouse models of brain development to the human brain. Hence, in 
vitro cultures of human NSCs, which are amenable to genetic manipulation, provide 
an accessible model for understanding normal and abnormal development of the 
nervous system in man. NSCs obtained from a diseased postmortem human fetal or 
adult brain can function as a cellular model to decipher the mechanisms of 
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pathogenesis of human neurological disorders, especially monogenic ones. For 
instance, NSCs obtained from brain specimens of Lesch–Nyhan-diseased human 
fetuses are being used to elucidate the causes of neurological dysfunction in Lesch–
Nyhan disease, an inherited disorder due to a deficiency of the enzyme 
hypoxanthine-phosphoribosyltransferase (HPRT) (Cristini et al., 2010). On the other 
hand, NSCs derived from patient-specific induced pluripotent stem (iPS) cells may 
provide a cellular model of neurodegenerative disorders where end-stage disease 
manifestations stymie the availability of NSCs from postmortem brain samples. (iPS 
cell-derived NSCs will be revisited in a later section.) 
Due to their capacity for substantial expansion in vitro, their ability to produce the 
repertoire of neural cells of the CNS and their amenability to genetic modification, 
NSCs present tremendous potential for application in cell replacement therapy and 
regenerative medicine. In general, there are two synergistic functions of NSCs that 
are utilized for regenerative therapy. The first, as indicated earlier, is the potential to 
generate functional cells to replace those that have become dysfunctional or 
eliminated in the diseased tissue. The second is the “chaperone” effect of NSCs, 
which is possibly part of the role of NSCs in sustaining development and 
homeostasis in the CNS (Ourednik et al., 2002). In essence, NSCs have been found 
to secrete growth factors, neurotrophins, cytokines and other factors that have 
neuroprotective and immunoregulatory effects, and thus may serve to ameliorate 
neurodegeneration and the disease condition (Blurton-Jones et al., 2009; Lee et al., 
2007). A plethora of transplantation studies performed in mammals presents 
encouraging findings that support the transplantation of exogenous NSCs and their 
progeny as an approach to regenerate damaged nervous system tissue (Armstrong 
et al., 2000; Brüstle et al., 1999; Davies et al., 2006; Gaillard et al., 2007; Keirstead 
et al., 2005; Kerr et al., 2003; Kim et al., 2002; Svendsen et al., 1997; Wernig et al., 
2008; Windrem et al., 2004; Yang and Yu, 2009). Several reports have found that 
6 
 
human NSCs can survive, migrate and generate functional neurons and glial cells 
(Cummings et al., 2005; Kelly et al., 2004; McBride et al., 2004; Wu et al., 2002), as 
well as provide neuroprotection (Lee et al., 2007; Suzuki et al., 2007), after in vivo 
xenografting into rodents; these reports provide the rationale behind the use of NSCs 
in clinical studies. 
Early clinical trials using human fetal mesencephalic tissue, which likely contained 
neuronal progenitors, for transplantation into Parkinson’s disease patients have 
shown that the transplanted cells could survive, innervate the host striatum and 
improve the disease condition, albeit with limited symptomatic relief and adverse 
effects such as dyskinesia occurring in a number of patients (Kordower et al., 1995; 
Lindvall, 1997; Lindvall et al., 1994). Results from these clinical trials have raised 
expectations of NSC-based therapy for the treatment of neurological disorders, like 
amyotrophic lateral sclerosis, Huntington’s and Alzheimer’s diseases. Following 
improved methods to isolate, propagate and enrich NSCs, there are currently more 
ongoing clinical trials involving the direct use of human NSC lines or patient-derived 
NSCs for treatment of a range of neurological conditions, including spinal cord injury, 
traumatic brain injury, age-related macular degeneration, Parkinson’s disease and 
neuronal ceroid lipofuscinosis (Levesque et al., 2009; Selden et al., 2008). One 
example is the ongoing phase I/II trial in chronic thoracic spinal cord injury by 
StemCells, Inc. involving the use of their proprietary human fetal-derived NSC line 
HuCNS-SC. (A list of ongoing clinical trials can be found at the US National Institute 
of Health Clinical Trials website: www.clinicaltrials.gov/). 
 
1.1.4 NSCs in cancer therapy 
NSCs and neural progenitors have been found to possess an inherent ability to 
migrate to pathological and malignant tumor sites within the brain as well as in the 
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periphery (Aboody et al., 2000; Brown et al., 2003; Schmidt et al., 2005). This tumor-
tropic property, along with the potential to engraft stably into the host brain and 
amenability to genetic manipulation (Benedetti et al., 2000), makes NSCs attractive 
candidates as cellular vehicles to deliver therapeutic agents or genes to brain tumors 
and metastases. Recent studies in animals have demonstrated that human NSCs, 
typically primary and immortalized NSCs, can be engineered to target anti-tumor 
genes, such as prodrug-activating enzyme cytosine deaminase (CD) and interferon-β 
(IFN-β), to experimental brain tumors and metastases (Ito et al., 2010; Kim, 2011; 
Shimato et al., 2007). Another commonly used prodrug-activating enzyme that is also 
currently utilized in our lab for suicide gene therapy of glioma is the herpes simplex 
virus thymidine kinase (HSVtk), which converts systematically administered 
ganciclovir (GCV) into the toxic DNA replication-inhibiting phosphorylated form (Zhao 
and Wang, 2010). The anti-tumor effect and prolonged survival of the tumor-
inoculated animals observed in these studies lend weight to the promise of human 
NSCs as delivery vehicles of therapeutic agents for clinical cancer therapy, and have 
spawned a series of clinical trials using immortalized human NSC lines (Kim, 2011; 
Najbauer et al., 2008). One such trial is a phase I trial for NSC-mediated therapy of 
recurrent high-grade gliomas with poor prognosis, which was initiated by City Hope 
National Medical Center in 2010, involving the use of the robustly characterized NSC 
line, HB1.F3.CD, which was derived from human fetal telencephalon and genetically 
engineered to express CD. 
Like most cell-based therapy, the effectiveness of NSC-based gene therapy is 
dependent on the ability of NSCs to target and infiltrate disease or tumor sites. 
Having a greater understanding of the molecular mechanisms involved in NSC-tumor 
tropism and the factors that drive them would help in fine-tuning the migratory 
specificity and sensitivity of NSCs to malignancies for improved efficacy of NSC-




1.1.5 Sources of human NSCs 
Renewable sources of NSCs are essential for both basic research and for NSC-
based therapies for neurological disorders and cancer. Various sources of human 
NSCs are discussed here. 
 
1.1.5.1 Fetal and adult NSCs 
The first population of human NSCs was isolated from the fetal CNS where NSCs are 
abundant in several regions. In human adults, NSCs are located in more specific 
regions such the SVZ and the hippocampus. Fetal and adult NSCs can be easily 
derived postmortem from the CNS of aborted fetuses or from the CNS parenchyma 
of adult cadavers, respectively, and enriched in vitro in neurosphere cultures. 
However, there are several caveats to consider regarding these sources of NSCs. 
Firstly, the constraints of limited availability of donor material to derive fetal and adult 
NSCs, the low rate of proliferation and the difficulty in long term propagation of fetal 
and adult NSCs in culture, render these sources unsuitable to meet the required 
economies of scale for therapeutic application. In addition, there are ethical concerns 
surrounding the use of NSCs from aborted fetuses. In contrast, the use of adult 
NSCs poses no ethical problems beyond consent, but they are likely regionally 
specified and display a more restricted differentiation potential (Maciaczyk et al., 
2009; Malatesta et al., 2003; Nunes et al., 2003). Depending on the region of the 
CNS from which they are isolated, adult NSCs can differentiate into very limited types 
of neural cells. Nevertheless, these NSCs can be immortalized by genetic 
modification, for example with Myc oncogene, and made into readily expandable 
clonal human NSC lines with enhanced capacity for self-renewal and proliferation 
(Kim et al., 2011). The major limitation of using immortalized NSC lines for clinical 
applications is the risk of aberrant growth, which may be circumvented by extensive 
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characterization of these cells. An immortalized human NSC line used in this study is 
ReNcell CX, which is a commercially available fetal cortical NSC line. Its availability 
makes it viable for studies aimed at deciphering the mechanisms of regulation of 
NSC differentiation. 
 
1.1.5.2 Pluripotent stem cell-derived NSCs 
Human embryonic stem cells (hESCs), which are pluripotent cells derived from the 
inner cell mass of blastocyst-stage embryos, offer a renewable and unlimited source 
of human NSCs. Many protocols have been reported to derive expandable NSC 
populations from hESC that are able to differentiate in a predictable and controlled 
manner to give rise to potentially any functional neural or neuronal cell type in the 
CNS (Chambers et al., 2009; Dhara and Stice, 2008; Reubinoff et al., 2001; 
Swistowski et al., 2009). Sidestepping the controversial ethical debate surrounding 
the procurement of hESCs, in vitro expanded NSCs derived from hESCs currently 
remains one of the most accessible model systems for developmental neurobiology 
studies in man, partly due to its high differentiation potential. Newly derived NSCs are 
likely to be at a similar stage in development as neuroepithelial cells of the embryo – 
the primordial NSC, and in prolong culture they are likely to develop characteristics 
more akin to fetal and adult NSCs (Kalyani et al., 1997; Shin et al., 2006). 
Additionally, NSCs derived from hESCs harbouring mutations for monogenic 
disorders present easy-access in vitro models of such diseases, including 
Huntington’s disease and neurofibromatosis-1 (Frumkin et al., 2010; Mateizel et al., 
2006), though the primary source of such mutation-bearing hESCs are hard to come 
by. 
The recent development of human induced pluripotent stem (iPS) cell technology by 
Yamanaka’s group opens the doors to the creation of autologous cellular therapies 
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(Yamanaka, 2007). Patient-specific NSCs for transplantation can be derived from iPS 
cells that were generated by reprogramming a patient’s own somatic cells 
(Swistowski et al., 2010). Unlike hESC-derived NSCs, the use of iPS cell-derived 
NSCs are not ethically problematic and they potentially eliminate the risk of immune 
rejection, although this ought not to be assumed indubitably (Zhao et al., 2011). 
Moreover, disease-specific iPS cell-derived NSCs and neural cells offer an 
unprecedented opportunity to recapitulate in vitro the mechanisms of human 
neurological disorders, thereby enabling a more faithful investigation of the disease 
progress. Towards that end, several disease-specific human iPS cell lines have been 
generated from patients with various neurodevelopmental and neurodegenerative 
disorders, such as amyotrophic lateral sclerosis (Dimos et al., 2008), Parkinson’s 
disease (Park et al., 2008), Rett syndrome (Hotta et al., 2009), Alzheimer’s disease 
(Israel et al., 2012) and Huntington’s disease (Zhang et al., 2010b). These in vitro 
models allow us to delve into the cellular and molecular events that underlie the 
“pathophysiological mechanism” of such diseases, which could prove valuable for 
neuropharmacological studies to screen for therapeutic agents and develop 
individualized cellular therapies. While the promise of iPS cell technology is great, 
there are challenges to overcome for their clinical application, such as the lengthy 
derivation of iPS cells, cell-intrinsic aberrations associated with reprogramming and 
the need for greater characterization of these cells. Several methods to generate 
integration-free iPS cells, such as the episomal DNA method, and to improve 
derivation efficiency are being developed to address these problems (Cheng et al., 
2012). An alternative to reprograming of terminally committed cells into iPS cells and 
then deriving NSCs is the direct reprograming of cells into NSCs and neural cells 
without reverting to a pluripotent state (Ring et al., 2012; Vierbuchen et al., 2010; 
Wang et al., 2012). 
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Though the directed differentiation of hESC or iPS cells into neural cell types has 
been extensively studied, there is still much to elucidate about the pathways and 
mechanisms underlying the differentiation process. Neural differentiation protocols 
are still mostly inefficient and yields of specific neuronal cell types are poor. A greater 
understanding of the mechanisms in hESC-based neural differentiation could 
translate into novel insights to dissect the process of NSC fate specification and 
human neurodevelopment. Additionally, it could lead to fine-tuning of protocols for 
efficient derivation, long-term maintenance and lineage-specific differentiation of 
NSCs. Hence, it is of interest to examine the molecular factors involved in self-
renewal and differentiation of NSCs. 
 
1.2 Factors regulating self-renewal and differentiation of 
NSCs 
NSCs in the nervous system self-renew by dividing symmetrically to give rise to two 
daughter cells that retain the NSC identity, or asymmetrically to produce one of itself 
and a more fate-restricted daughter cell. It is believed that symmetric divisions of 
NSCs predominate during embryonic development but switch to asymmetric divisions 
to generate greater numbers of differentiated functional neural cells in later stages of 
development. This decision to self-renew or differentiate into lineage-restricted 
progenitors and committed cells is regulated by a network of factors, which include 
cell-intrinsic determinants, such as transcription factors and non-coding RNAs, or 
cell-extrinsic cues, such as growth factors, cytokines and the extracellular matrix. 
Understanding how these factors function and interact to modulate self-renewal and 
fate specification could prove useful for improving methods to derive and maintain 





1.2.1 Transcription factors 
Transcription factors are DNA-binding proteins that recognize and bind to specific 
DNA sequences in regulatory elements of genes to activate or repress gene 
expression. They constitute the largest family of proteins in humans and have critical 
roles in development (Lander et al., 2001). In essence, mammalian embryonic 
development proceeds in a tightly regulated manner as a series of differential gene 
expression programs coordinated by the sequential activation or inactivation of 
transcription factors. There is an increasing amount of information implicating a 
number of transcription factors as regulators of NSC self-renewal and lineage 
specification (reviewed in Bertrand et al., 2002; Ming and Song, 2011; Thompson 
and Ziman, 2011; Yun et al., 2010). Repressor element-1 silencing transcription 
factor (REST), ATF5, Sox genes, Pax genes and the orphan nuclear receptor Tailess 
(TLX) are a few examples of proneural transcription factors involved in neural 
determination and maintaining the NSC state by suppressing differentiation in 
mammalian NSCs (Graham et al., 2003; Qureshi et al., 2010; Shi et al., 2004). On 
the other hand, Neurogenin1 (Ngn1),  mammalian achaete-scute homologue 1 
(Mash1) and some Pax genes have been found to promote neuronal fate 
specification (Kageyama et al., 2005). In addition, following the groundbreaking work 
of Yamanaka’s group in reprogramming differentiated cells into iPS cells, others have 
successfully reprogrammed fibroblasts directly into NSCs or neuronal cells by the 
expression of neural-specific transcription factors, including Sox2, Pax6 and Olig2 
(Han et al., 2012; Lujan et al., 2012; Ring et al., 2012; Thier et al., 2012). These 
studies highlight the importance of transcription factors in conferring ‘neural 
stemness’ and determining cell fate. In this study, we restrict our focus to the factors 





The paired box protein PAX6 is an evolutionarily conserved transcription factor that 
has garnered significant research interest due to its role in a variety of ocular defects, 
including aniridia (Jordan et al., 1992). Studies across a variety of animal models, 
from Drosophila to humans, have established Pax6 to be a crucial regulator of 
development in the eye, pancreas and nervous system (reviewed in Georgala et al., 
2011). In mice, Pax6 is expressed in region-specific neural progenitors only after 
closure of the neural tube (Schmahl et al., 1993), whereas in humans it is uniformly 
expressed in early neuroectodermal cells (cells from which neural progenitors and all 
other neural cell types originated) derived from fetuses and from hESCs (Pankratz et 
al., 2007), thus adumbrating its possible role as an early inducer of neuroectoderm 
fate in man. In rodents, Pax6 is expressed in neural stem/progenitor cells in the 
subgranular zone (SGZ) of the hippocampal dentate gyrus, and in the ependymal 
layer and SVZ of the lateral ventricle of the postnatal brain (Hack et al., 2005; 
Maekawa et al., 2005). Quinn et al. (2007) demonstrated using Pax6+/+↔Pax6–/– 
chimeric mice (as the Pax6-null mutation is neonatal lethal) that Pax6 regulates the 
proliferation of neural progenitors and loss of Pax6 led to early depletion of neural 
progenitor cell populations, which corroborate earlier findings in Pax6-deficient rats 
(Maekawa et al., 2005; Quinn et al., 2007). More recently, the human PAX6 gene 
was demonstrated to be a determinant of the human neuroectoderm cell fate (Zhang 
et al., 2010c). These studies together highlight that Pax6 is crucial for the 
maintenance of NSCs and thus is commonly used as a molecular marker for human 
NSCs. 
The human PAX6 protein exists in three major isoforms due to alternative splicing, 
namely, PAX6a, PAX6b and PAX6(PD). PAX6a contains two DNA-binding domains, 
which includes the canonical N-terminal paired domain (PD) comprised of 128 amino 
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acid resides and a homeodomain (HD), and a proline-serine-threonine-rich 
transactivation domain. The other PAX6 spliced variant, PAX6b, has an additional 
exon-5a-encoded 14-amino-acid insertion in its PD that confers upon it different 
DNA-binding properties compared with the PAX6a isoform (Carriere et al., 1993; 
Epstein et al., 1994; Kozmik et al., 1997). In contrast, the PAX6(PD) isoform lacks 
the PD. The three isoforms each display a distinct expression pattern and possess a 
different function. Isoforms PAX6a and PAX6b are expressed in the CNS, whereas 
Pax6(PD) expression is restricted to the developing eye and olfactory bulb (Kim and 
Lauderdale, 2006). Likewise, early human neuroectodermal cells expressed PAX6a 
and PAX6b, but not PAX6(PD). The recent study by Zhang et al. (2010c) 
demonstrated that PAX6 is both necessary and sufficient to induce neuroectoderm 
specification of hESCs. The silencing of PAX6 in hESCs impedes differentiation and 
retains pluripotency, whereas overexpression of PAX6 represses pluripotent genes 
and promotes neural induction. They further demonstrated that while both PAX6a 
and PAX6b induced the repression of pluripotent genes only PAX6a promoted 
neuroectoderm specification of the cells, but both isoforms work together to 
coordinate the full transition from pluripotency to the neuroectodermal fate. Moreover, 
comparisons with mouse ESCs revealed that the distinctive neural-inducing ability of 
PAX6 is unique to hESCs. 
Although PAX6 may be important for maintaining NSCs and neural progenitors, it has 
also been shown to promote neurogenesis in a context-dependent manner (reviewed 
in Thompson and Ziman, 2011). Incipient evidence of the neurogenic effect of Pax6 
came from expression profile studies in mice that found strong Pax6 expression in 
neurons in various brain regions, including the olfactory bulb, amygdala and 
cerebellum (Stoykova and Gruss, 1994), and from studies on Pax6-mutant rodents 
which developed drastically smaller cerebral cortices with improper cortical 
lamination (Heins et al., 2002; Schmahl et al., 1993). Furthermore, premature death 
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of neurons in the cortex of Pax6-mutant rats and of neurons derived from Pax6-
mutant mouse ESCs were observed (Nikoletopoulou et al., 2007; Quinn et al., 2007). 
In reverse, overexpression of Pax6 in mouse embryonic cortical and striatal cells, 
adult mouse SVZ cells, and in the developing cortex of transgenic mice resulted in 
increased neurogenesis (Berger et al., 2007; Hack et al., 2005; Hack et al., 2004; 
Heins et al., 2002). Additionally, findings that the ectopic expression of Pax6 in 
astrocytes of the postnatal mouse cortex could drive the cells towards neuronal 
phenotype further support the evident pro-neurogenic effect of mammalian Pax6 
gene (Berninger et al., 2007). More importantly, the recent study by Kallur et al. 
(2008) illustrated the ability of PAX6 to promote neurogenesis in human primary 
NSCs. They showed that overexpression of PAX6 in human fetal striatal NSCs 
generated increased numbers of region-specific neurons with concomitant reduction 
in numbers of glial fibrillary acidic protein (GFAP)-expressing glial cells in vitro and in 
vivo. Further corroboration of this finding comes from another study (Mo and Zecevic, 
2008) that showed decreased neurogenesis and increased astrogenesis after PAX6 
knockdown in PAX6+ human fetal NSCs. The versatility of PAX6 in 
neurodevelopment comes from its ability to regulate a variety of downstream genes 
by changing the combination of co-binding transcription factors in a dose-dependent 
manner (Sansom et al., 2009), thus depending on which co-transcriptional factor it is 
bound to it regulates a specific set of genes to either maintain stem cell renewal or 
initiate neuronal differentiation. 
 
1.2.1.2 SOX2 
Sex-determining region Y-box 2 (SOX2) is a member of the SOX family of 
transcription factors that possess high-mobility group (HMG)-box domains, which are 
highly conserved DNA-binding domains. In recent years, Sox2 has become widely 
regarded as a reprogramming factor important for inducing and maintaining 
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pluripotency in ESCs. Yet, it also has important functions in neurodevelopment. 
Across different species from Xenopus to human, Sox2 shows conserved expression 
early in the nascent neural plate and has a critical role in early development of the 
CNS (Wegner and Stolt, 2005). Studies using Sox2-βgeo or Sox2-eGFP transgenic 
mice have revealed that Sox2 is expressed predominantly in proliferating NSCs and 
progenitors throughout the developing CNS and, postnatally, in neurogenic regions of 
the adult CNS such as the SVZ, SGZ and the hippocampal dentate gyrus (Ellis et al., 
2004; Suh et al., 2007; Zappone et al., 2000). Further in vivo lineage tracing and in 
vitro characterization of these Sox2-expressing cells show that they possess the 
functional characteristics of NSCs including multipotentiality and the capacity to self-
renew. Taken together, these studies suggest that Sox2 serves as a universal stem 
cell marker and may be used to identify and isolate NSCs. 
Gain-of-function and loss-of-function studies in Xenopus provide the first few 
evidences of the role of Sox2 in maintaining ‘stemness’ in NSCs. Antagonism of 
Sox2 function by expressing a dominant-negative form of Sox2 inhibited early neural 
development in Xenopus embryos and indicated the importance of Sox2 in 
maintaining the neural identity of neuroectodermal cells during neural differentiation 
(Kishi et al., 2000). Furthermore, overexpression of Sox2 biased uncommitted mouse 
ESCs towards the neuroectodermal lineage while detracting from the mesodermal or 
endodermal fate (Zhao et al., 2004), and was responsible for reprogramming rat 
oligodendrocyte precursor cells into NSC-like cells (Kondo and Raff, 2004). 
Functional studies in mice demonstrated that the ablation of Sox2 in Sox2 compound 
heterozygous mice, which carry one Sox2-null and one Sox2-hypomorphic allele, 
caused substantial neurological defects such as a reduction in cortex size, loss of 
thalamo-striatal parenchyma and epilepsy (Ferri et al., 2004). On closer examination, 
these mutants exhibited significant loss of proliferating progenitors in the SVZ and 
the dentate gyrus. In another study, Favaro et al. (2009) found that conditional 
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deletion of Sox2 in the CNS, with complete Sox2 loss occurring after early stages of 
neural development, resulted in minor brain defects in mutant mice at birth but led to 
severe loss of NSCs and neurogenesis in the postnatal hippocampus. Hence, these 
studies implicate Sox2 in the proliferation and maintenance of both embryonic and 
postnatal NSCs. 
In general, Sox2 expression is downregulated when NSCs and progenitors undergo 
differentiation. Strikingly though, several studies have implicated Sox2 function in 
neuronal differentiation. NSCs derived from the brains of Sox2-hypomorphic mutant 
mice exhibit defective neuronal differentiation, albeit with relatively unimpaired self-
renewal (Cavallaro et al., 2008); it is likely that other Sox genes such as Sox1 and 
Sox3 can partially compensate for the function of Sox2 in self-renewal (Wegner and 
Stolt, 2005; Wood and Episkopou, 1999). These Sox2-deficient NSCs could be 
differentiated in vitro into β3-tubulin-positive cells, an indication of immature neurons; 
however, these cells showed poor arborization and were negative for mature 
neuronal markers such as MAP2. Rescue of the neuronal maturation defect by Sox2 
overexpression was possible at the early proliferating stages but not at late 
postmitotic stages of neuronal differentiation (Cavallaro et al., 2008). Likewise, in vivo 
investigation of GABAergic neurons in the Sox2-hypomorphic mutants showed 
reduction in cell numbers and significant neuronal maturation defects including the 
delayed migration of these interneurons, consistent with neuronal loss and reduced 
cortical extensions reported in other studies (Cavallaro et al., 2008; Ferri et al., 2004). 
Interestingly, Cavallaro et al. (2008) also found that Sox2 directly targets the GFAP 
gene and represses endogenous expression of GFAP, an astroglial marker. A 
separate study examining the effect of Sox2-hypomorphic mutation in the mouse 
retina also demonstrated that Sox2 has a key role in conferring retinal ganglion cells, 
which are the neural progenitors of the retina, the competence to proliferate and 
differentiate into functional retinal neurons(Taranova et al., 2006). These findings, put 
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together, are indicative of the plausible role of Sox2 in neural differentiation – to 
‘prime’ a NSC/progenitor for later neuronal differentiation events and to suppress glial 
differentiation events. 
Intriguingly, many of these studies in mice reveal that the range of phenotypes 
observed, from loss of NSCs to impaired neuronal differentiation, corresponds to the 
degree of Sox2 deficiency and to the spatio-temporal occurrence of the deficiency, 
thus demonstrating that the function of Sox2 is dose-dependent and context-
dependent (reviewed in Pevny and Nicolis, 2010). In humans, mutations in SOX2 
result in a range of neurological and developmental disorders, such as cognitive 
abnormalities, epilepsy, seizures, anophthalmia and hippocampal malformations, 
similar to the defects observed in the different Sox2-mutant mice (Fantes et al., 2003; 
Kelberman et al., 2006; Sisodiya et al., 2006). Likewise, this broad range of severity 
of the disorders associated with the heterozygous loss-of-function mutations in SOX2 
is telltale of the dose-dependent function of human SOX2. A reasonable explanation 
for the dosage and context dependence of Sox2 function is that the specificity of 
action of Sox2 on target genes is determined by its interaction with cofactors. 
Accordingly, different concentrations (dose) of Sox2 together with the availability 
(context) of different cofactors for binding may give rise to a combination of protein 
dimers or complexes that forms varying structural interfaces with a variety of DNA 
regulatory sequences, ultimately resulting in different transcriptional outcomes. Two 
examples of cofactors that interact with Sox2 include Pax6, which binds with Sox2 to 
form a DNA-binding complex that activates transcription of the -crystalline gene to 
initiate lens development in mouse (Kamachi et al., 2001), and Oct4, which co-
occupies specific gene regulatory sequences with Sox2 to activate transcription of 
‘stemness’ genes in ESCs. 
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Perhaps the most salient evidence for the role of SOX2 as a key regulator for self-
renewal and maintenance of the functional identity of human NSCs is provided by the 
recent finding that SOX2 alone is sufficient to reprogram human fibroblasts into 
multipotent NSCs (Ring et al., 2012). 
 
1.2.2 Extracellular factors 
The endogenous NSC in the brain resides in specialized microenvironments or 
niches that preserve its multipotency and self-renewing properties. Though much of 
the stem cell niche still remains unknown, studies on the NSC niche have identified 
specific extracellular cues that regulate NSC proliferation, self-renewal and fate 
specification of NSC progeny and have proven useful for the isolation and expansion 
of NSCs in culture. Some of these extracellular factors include trophic factors and 
extracellular matrices. 
A number of growth factors, cytokines and mitogens that affect the survival, 
proliferation and differentiation of NSCs have been identified by in vivo studies of the 
various neurogenic niches in the rodent brain and by in vitro experimentation on NSC 
cultures (Lillien, 1995; Oshima et al., 2007; Raballo et al., 2000). Identification of 
these trophic factors has been crucial to the isolation and culture of NSCs, where the 
ability to expand cell numbers while holding differentiation in abeyance is prized, and 
in directing the differentiation of NSCs into specific cell types in vitro. Some of these 
soluble factors are secreted by endothelial cells and astrocytes that are in close 
contact with NSCs in the niche (Shen et al., 2004; Song et al., 2002). Epidermal 
growth factor (EGF) and bFGF are two growth factors that are key factors in 
maintaining proliferation and self-renewal of mouse and human NSCs in culture and 
in the milieu of the brain (Conti et al., 2005; Gritti et al., 1999; Raballo et al., 2000; 
Vescovi et al., 1999). Moreover, these two growth factors, when infused into mice 
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brain after ischemia, were shown to be able to stimulate endogenous NSCs and 
progenitors for functional repair (Nakatomi et al., 2002). The cytokine leukemia 
inhibitory factor (LIF) is another mitogen that was recently found to support NSC self-
renewal (Galli et al., 2000; Pitman et al., 2004; Wright et al., 2003). Based on in vivo 
studies in mice, it is likely to play a dual role in promoting self-renewal of neural 
progenitors and survival of neurons (Murphy et al., 1993; Richards et al., 1996). In 
human NSC and progenitor cultures, LIF, when used in combination with bFGF or 
EGF, has been shown to improve cell viability, prolong doubling capacity and delay 
terminal senescence (Galli et al., 2000; Wright et al., 2003). Endothelial cells also 
secrete a variety of other factors known to promote differentiation and neuronal 
survival, including vascular endothelial growth factor (VEGF), platelet-derived growth 
factor (PDGF), interleukin-8 (IL-8) and brain-derived neurotrophic factor (BDNF) (Jin 
et al., 2002; Palmer et al., 2000). 
Cells in the niche also secrete proteins that form the extracellular matrix. Besides, 
providing physical support, the extracellular matrix in the niche plays a pivotal role of 
regulating NSC function by mediating intercellular communication and sequestering 
soluble trophic factors (Alvarez-Buylla and Lim, 2004). Laminin is an extracellular 
matrix that has been shown to be permissive for NSC proliferation and differentiation 
(Flanagan et al., 2006). Extracellular matrices interact with specific receptors on the 
surfaces of cells, such as integrins, to activate pathways that modulate a wide array 
of cellular functions, including survival, proliferation and migration. In general, 
extracellular cues activate intracellular signaling pathways, such as the Notch, Wnt, 
JAK-STAT and MAP kinase pathways, to effectuate transcriptional regulation (Wen 




1.2.3 Epigenetic factors 
Besides the interplay of environmental cues and transcription factors, epigenetic 
factors also regulate the transition from self-renewal to fate commitment in NSCs. 
There is growing evidence that NSCs and neural progenitors bear specific epigenetic 
marks that keep developmental genes that define specific cell fates in either a 
transcriptionally repressed or ready state and therefore contribute to fate 
specification (Hirabayashi and Gotoh, 2010; Massirer et al., 2011). These epigenetic 
factors place uncommitted cells in a ‘poised state’ to self-renew or differentiate along 
a restricted path in response to appropriate intrinsic and extrinsic cues. Some of the 
main epigenetic mechanisms that regulate NSC self-renewal and differentiation 
include DNA methylation, histone modification and non-coding RNA. 
DNA methylation and histone modification are the main mechanisms regulating the 
epigenetic marks that determine transcriptional activity in NSCs (Shen et al., 2005; 
Takizawa et al., 2001). They alter the accessibility of genomic DNA to transcription 
factors by modulating the structure of chromatin. With regard to DNA methylation, 
DNA methyltransferases catalyze the methylation of cytosine at CpG dinucleotides in 
genomic DNA, resulting in changes to DNA structure (Bolden et al., 1986) or 
recruitment of methyl-CpG-binding domain (MBD)-containing proteins that bind to 
sequences with methylated CpG dinucleotides (Nan et al., 1997) to obstruct binding 
of transcription factors to their target genomic sequences. Several studies have 
found that the methylation status of glial or neuronal lineage specific genes affects 
NSC differentiation (Hatada et al., 2008; Kishi and Macklis, 2004; Takizawa et al., 
2001). It has been suggested that manipulating the methylation status of neural 
genes in NSCs through the use of small molecules may be a plausible method to 
derive specific neuronal or glial cell types efficiently, like in the case of 
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reprogramming somatic cells into iPS cells (Huangfu et al., 2008; Mikkelsen et al., 
2008). 
Non-coding RNAs are gaining attention for their role in regulating a number of 
epigenetic events, such as gene imprinting and RNAi-mediated gene silencing 
(Grewal and Moazed, 2003; He and Hannon, 2004). They contribute to an additional 
layer of epigenetic control through their interaction with transcription factors and 
chromatin modifiers. MicroRNAs (miRNAs) are one prominent class of non-coding 
RNAs that have been extensively studied for their roles in NSC self-renewal and 
differentiation. Hence, miRNAs are a main focus of this study and will be discussed in 




MicroRNAs (miRNAs) constitute a class of short non-coding RNAs of 19-25 
nucleotides in length that function typically as post-transcriptional regulators of gene 
expression. They were first discovered by Ambros and colleagues who reported 
finding a 22-nucleotide lin-4 RNA transcript in Caenorhabditis elegans that can bind 
to the lin-14 transcript and regulate LIN-14 protein expression (Lee et al., 1993). 
Since then, miRNAs have been found to be ubiquitously present in most metazoans, 
from worms to mammals (Bartel, 2009). Currently, there are more than 1000 known 
miRNAs in the human genome and this number is still growing (Kozomara and 
Griffiths-Jones, 2011). They establish complex post-transcriptional regulatory 
networks as each miRNA may target multiple genes and each gene may be targeted 
by multiple miRNAs. It is predicted that each miRNA targets about 200 genes in 
mammals and accordingly, the mammalian ‘miRNAome’ is predicted to regulate 
more than 30% of all protein-coding genes (Krek et al., 2005; Xie et al., 2005). Hence 
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as key regulators of gene expression, miRNAs have been implicated in a diverse 
array of biological and pathological processes, ranging from cell survival, cell death, 
differentiation, development of the CNS, to cancer. 
 
1.3.2 Biogenesis 
At least two-thirds of all human miRNAs are encoded intragenically in exons lacking 
protein coding potential or in introns of protein-coding genes (Rodriguez et al., 2004). 
Some may even be encoded in intergenic regions on a chromosome. Additionally, 
they may be encoded either monocistronically in single standalone genes or 
polycistronically in clusters. In general, the biogenesis of miRNAs begins in the 
nucleus with the transcription miRNA genes into long primary transcripts, known as 
primary miRNA (pri-miRNA). Intragenic miRNAs are transcribed together with their 
host gene and using the transcriptional regulatory elements of their host gene, 
whereas intergenic miRNAs possess their own promoters for transcription (Bartel, 
2004). Like protein-coding genes, majority of miRNAs are transcribed by RNA 
polymerase II, with the exception of a few miRNAs being transcribed by RNA 
polymerase III (Borchert et al., 2006), resulting in 5’ end-capped and 3’ end-
polyadenylated pri-miRNAs that contain one or more 60- to 80-nucleotide hairpin 
stem-loop structures (Lee et al., 2004). This hairpin-shaped structure in pri-miRNA is 
cleaved by a nuclear microprocessor complex, comprising the RNase III 
endonuclease Drosha and its cofactor DGCR8, near the base of the stem to release 
a ~60- to 70-nucleotide precursor miRNA (pre-miRNA), which carries a ~20-bp stem, 
a loop and a 2-nucleotide 3’-overhang (Denli et al., 2004; Lee et al., 2003). The pre-
miRNA is subsequently exported out of the nucleus to the cytoplasm by Exportin-5 
(Yi et al., 2003), and further cleaved by the cytoplasmic RNase III endonuclease 
Dicer to generate a ~22-nucleotide mature miRNA duplex (miRNA/miRNA*) 
(Hutvagner et al., 2001). One strand of the miRNA duplex, usually the one with 
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weaker base pairing to the complementary strand at its 5’ end, is assembled together 
with a member from the Argonaute (Ago) family of proteins into a ribonucleoprotein 
complex known as the miRNA-induced silencing complex (miRISC), which mediates 
gene silencing by messenger RNA (mRNA) degradation or translational repression 
(Khvorova et al., 2003). This strand is referred to as the guide strand. The 
complementary strand, known as the passenger strand or miRNA*, is degraded in 
most cases and present in lower levels than the guide strand (Schwarz et al., 2003). 
Nevertheless, have been reports that the miRNA* species in various contexts can 
exist at levels comparable to the guide strand and exert regulatory function (Okamura 
et al., 2008; Yang et al., 2011). Figure 1.1 provides a general scheme of miRNA 






Figure 1.1 Biogenesis of microRNAs. Schematic representation of the general 
molecular mechanism of miRNA biogenesis. miRNAs are transcribed by RNA polymerase 
II or III as primary miRNA (pri-miRNA) transcripts that are capped and polyadenylated. 
Pri-miRNAs are then cleaved by the nuclear microprocessor complex consisting of Drosha 
and DGCR8 into precursor miRNAs (pre-miRNAs) bearing stem-loop structures. The pre-
miRNA is then exported to the cytoplasm by Exportin-5/Ran-GTP complex and processed 
by the cytoplasmic RNase, Dicer into ~20 bp mature miRNA duplex. Subsequently, one 
strand of the duplex, the guide strand, is incorporated into RISC which contains Ago 
protein. The miRNA-RISC binds to target mRNA and mediates gene silencing by 
repressing translation or effectuating degradation of the target mRNA. (Figure from Shukla 
et al., 2011). 
1Figure 1.1 Biogenesis of microRNAs 
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1.3.3 Mechanism of action 
1.3.3.1 Target recognition 
The primary determinant of the gene regulatory function of a miRNA is its recognition 
and binding of target mRNA. miRNAs bind to their target mRNA not only through 
Watson-Crick base-pairing but also through the use of G:U wobble pairing, especially 
in metazoans (Didiano and Hobert, 2006; Miranda et al., 2006). In plants, most 
miRNAs bind to their target mRNAs with near-perfect complementarity that result in 
endonucleolytic cleavage of mRNA (Jones-Rhoades et al., 2006). On the contrary, 
metazoan miRNAs rarely bind to target mRNA with such extensive complementarity 
and display moderate effects on gene expression by fine-tuning protein translation 
rather than degrading mRNA. 
The core feature of miRNA targeting is the perfect contiguous base-pairing of the 
seed sequence of the miRNA, the segment of miRNA spanning the 2nd to the 7th/8th 
nucleotide from the 5’ end, with its cognate mRNA target site (Brodersen and Voinnet, 
2009); and though this pairing is regarded to be necessary for miRISC function, there 
are exceptions to the rule. Examples include the imperfect complementarity between 
the seed sequence of C. elegans miRNA, let-7, and its functional target sites in the 
lin-41 transcript (Friedman et al., 2009), as well as the existence of functional 
‘seedless’ target sites for miR-24 in various genes (Lal et al., 2009). From the 
example of miR-24, it is evident that extensive pairing with the 3’ half of the miRNA 
may compensate for the loss of seed matches. Furthermore, under the typical 
circumstance of seed sequence match, complementarity between the 3’ half of the 
miRNA and the target mRNA also serves to stabilize the miRNA-mRNA duplex. 
Another common feature of metazoan miRNA targeting includes the presence of 
mismatches and bulges in the central portions of the miRNA-mRNA duplex, which 
precludes cleavage of mRNA (Sun et al., 2010). In addition, the majority of functional 
miRNA target sites are located in the 3’ untranslated region (UTR) of target mRNA, a 
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reasonable expectation since the mRNA coding sequence is ‘shielded’ by ribosomes 
during protein translation (Friedman et al., 2009). Nevertheless, there are exceptions 
where functional miRNA recognition sites are also found in the 5’ UTR and in the 
coding sequence of mRNAs (Lytle et al., 2007; Tay et al., 2008). 
Due to the diverse conditions and low stringency of miRNA targeting, one gene may 
carry multiple target sites for a particular miRNA or several target sites for multiple 
miRNAs, which suggests the possibly of cooperative gene repression exerted by 
several miRISC complexes of the same miRNA or of multiple miRNAs. Furthermore, 
such complexity necessitates that miRNA target sites predicted by bioinformatics 
approaches be validated experimentally. 
 
1.3.3.2 Target gene silencing 
In general, the miRNA-incorporated miRISC assembly mediates post-transcriptional 
gene silencing by a few known mechanisms. These include direct translational 
repression by inhibiting translation initiation, elongation or termination, and indirect 
translational repression by mRNA cleavage or mRNA deadenylation (Figure 1.2). 
The miRNA-loaded miRISC assembly blocks the initiation of translation by inhibiting 
the recruitment and assembly of the 40S and 60S ribosome subunits (Figure 1.2A). 
One way by which the miRISC complex may mediate this effect is through interaction 
with eIF6, a key factor involved in 60S ribosome biogenesis, which results in 
obviation of ribosome assembly near the 5’ cap of the targeted mRNA (Chendrimada 
et al., 2007). Post-initiation, the miRISC complex may disrupt the elongation step of 
protein synthesis by inducing ribosomal drop-off or by obstructing the progression of 
elongation (Petersen et al., 2006). 
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In rare cases where the miRNA forms extensive base-pairing with its target mRNA, 
the target mRNA may be cleaved and degraded. mRNA cleavage in mammalian cells 
is mediated by AGO2, the only member of the Ago protein family known to direct 
cleavage of RNA duplexes through its RNase H domain, in the RISC assembly 
(Meister et al., 2004). Predominantly, mammalian miRNAs share partial 
complementarity with target mRNAs, and may induce destabilization and degradation 
of their target mRNAs by catalyzing their deadenylation and decapping (Figure 1.2B) 
(Bagga et al., 2005; Eulalio et al., 2007; Wu et al., 2006). Destabilized mRNAs are 
subsequently degraded or sequestered in cytoplasmic P bodies (Eulalio et al., 2007; 
Valencia-Sanchez et al., 2006). While the cognate mRNA provides clues regarding 
the mechanism by which a given miRNA may induce gene repression, it is still 
difficult to predict the exact outcome as structural determinants of the miRNA-mRNA 
duplex and the accessory proteins in the miRISC assembly influence the mode of 
repression (Eulalio et al., 2007). 
Contrary to their ‘conventional’ gene-silencing function, miRNAs have also been 
found to activate target mRNA expression during specific stages in the cell cycle 
(Vasudevan et al., 2007). However, the exact mechanism behind miRNA-mediated 






Figure 1.2 Mechanisms of miRNA-mediated post-transcriptional repression. (A) The 
miRISC-mRNA interaction can mediate several mechanisms of direct translational 
repression. These include initiation block, whereby the assembly of the 40S and 60S 
ribosomal subunits near the 5’ cap of mRNA is inhibited; ribosomal drop-off, whereby the 
40S/60S ribosomes are dissociated from mRNA; and stalled elongation, whereby 
ribosomes are prohibited from joining during progression of elongation. (B) Indirect 
translational repression by miRISC may occur via deadenylation, which involves the 
removal of the 3’ poly-A tail of mRNA, resulting in destabilization of target mRNA and their 
subsequent degradation or sequestration in P bodies. (Figure from Sun et al., 2010). 
 
2Figure 1.2 Mechanisms of miRNA-mediated post-transcriptional repression 
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1.3.4 miRNAs in NSC  self-renewal and fate commitment 
The expression of miRNAs is tightly regulated in a tissue- and developmental stage-
specific manner. Many studies have found some of these small RNAs to be crucial 
post-transcriptional regulators of stem cell self-renewal and lineage commitment, 
while several others have identified brain-specific or brain-enriched miRNAs with 
regulatory functions in various processes such as neurogenesis, synaptic plasticity 
and cognition (Cheng et al., 2009; Magill et al., 2010; Schratt et al., 2006; Zhao et al., 
2010; Zhao et al., 2009). 
The importance of miRNAs in development is evinced by studies demonstrating that 
the deletion of genes encoding vital components of the miRNA processing machinery, 
such as Dicer or Ago proteins, resulted in loss of stem cell populations and 
embryonic lethality in mice (Bernstein et al., 2003; Carmell et al., 2002; Murchison et 
al., 2005). A study (De Pietri Tonelli et al., 2008) showing that conditional knock-out 
of Dicer in the developing mouse cerebral cortex caused a significant reduction in the 
size of the postnatal cerebral cortex with signs of defective neuronal layering, albeit 
without impairment of the early expansion of NSCs and neural progenitors, highlights 
the key role of miRNAs in modulating neurogenesis. Furthermore, a recent study by 
Zheng et al. (2010) reported that conditional knock-out of Dicer in the ventral 
epithelium of developing mice disrupted the development of astrocytes and 
oligodendrocytes in the ventral spinal cord, thus supporting a role for miRNAs in 
initiating gliogenesis in the developing spinal cord. 
A few miRNAs have been identified to be involved in NSC self-renewal and fate 
determination based on their expression patterns, computationally-predicted and/or 
experimentally-verified targets, and overexpression analyses (Conaco et al., 2006; 
Shi et al., 2010; Zhao et al., 2010; Zhao et al., 2009). One of the most abundantly 
expressed miRNAs in the brain is miR-124; it is estimated to constitute 25–50% of 
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total miRNAs in the adult mouse brain (Lagos-Quintana et al., 2002). miR-124 is 
lowly expressed in self-renewing neural progenitor cells, but is upregulated during 
neuronal differentiation and highly expressed in mature neurons (Deo et al., 2006). 
Ectopic expression of miR-124 in NSCs and neural progenitors induced cell cycle exit 
and precocious neuronal differentiation, while knockdown of miR-124 abated 
neuronal differentiation and, though not sufficient to induce gliogenesis per se, 
instead maintained NSCs as dividing precursors (Cheng et al., 2009; Conaco et al., 
2006). miR-124 likely exerts its neurogenic effects by mediating the repression of 
anti-neuronal genes, such as REST and SCP1 (Visvanathan et al., 2007). REST, 
which is expressed in NSCs and non-neuronal cells including mouse ESCs, in turn 
can silence miR-124 expression and form a regulatory loop. Additionally, miR-124 
may activate neuron-specific alternative splicing by repressing PTBP1 expression, a 
gene encoding a repressor of pre-mRNA splicing, during neuronal differentiation 
(Makeyev et al., 2007). 
miR-9 is another brain-specific miRNA that is expressed preferentially in neurogenic 
regions of embryonic and adult brains (Krichevsky et al., 2003; Lagos-Quintana et al., 
2002). In NSCs, miR-9 targets and represses expression of the orphan nuclear 
receptor TLX (Krichevsky et al., 2006; Zhao et al., 2009). In turn, TLX, a regulator of 
NSC self-renewal that is highly expressed in NSCs and is downregulated upon 
differentiation, functions as a transcriptional repressor of miR-9, thus establishing a 
negative feedback loop with miR-9 (Shi et al., 2004). In contrast, miR-9 shows low 
expression in NSCs and increased expression during neuronal differentiation. 
Overexpression of miR-9 in NSCs resulted in impaired NSC proliferation and 
accelerated differentiation – effects reminiscent of TLX knockdown – which may be 
rescued by reconstitution of TLX function. Inversely, miR-9 inhibition promoted NSC 
proliferation (Zhao et al., 2009). Furthermore, miR-9 and miR-9* may target REST 
and CoREST, a cofactor of REST, respectively, to promote neural differentiation 
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(Qureshi et al., 2010). They are also reciprocally regulated by REST, thus forming 
another regulatory feedback loop (Packer et al., 2008). The prominent feature of 
regulatory loops between miRNAs and transcription factors may serve to control the 
delicate balance between NSC self-renewal and differentiation. 
The expression of both miR-124 and miR-9/miR-9* together has recently been found 
to be capable of reprogramming human fibroblasts into neurons (Yoo et al., 2011), 
thus highlighting their role in neuronal differentiation in man. Other miRNAs that have 
been identified to be regulators of NSC proliferation and fate specification include let-
7b, which also targets TLX, miR-137 and miR-184 (Liu et al., 2010; Szulwach et al., 
2010; Zhao et al., 2010). Nevertheless, while these studies evidently reveal that 
miRNAs have an important role in regulating NSC differentiation, most were carried 
out in rodents and their relevance to human development still requires further 
investigation. 
Hence, for this study, our interest lies in identifying miRNAs that modulate 
differentiation in human NSCs by acting on key fate-determining transcription factors. 
The study by Cheng et al. (2009) provides a proof of concept. They demonstrated 
that a mechanism of miR-124-mediated regulation of neuronal differentiation in 
mouse adult neural precursors from the SVZ was likely through direct targeting of 
Sox9, a Sox transcription factor involved in glial fate specification (Finzsch et al., 
2008; Stolt et al., 2003), by miR-124. 
 
1.4 Aims and objectives 
Although the functional properties of human NSCs, in terms of its tumor-homing, in 
vivo regenerative and in vitro differentiation capacities, have been extensively studied, 
the molecular mechanisms underlying NSC self-renewal and lineage specification 
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are incompletely, if not poorly, understood. Such knowledge is essential to develop 
improved protocols to efficiently derive homogeneous numbers of NSCs and the full 
range of their derivatives to meet the demands of translating NSC-based therapeutic 
strategies into clinical applications (Breunig et al., 2011). 
Several studies have identified miRNAs to be regulators of NSC self-renewal and 
lineage specification in rodents (discussed in Section 1.3.4), but little is known about 
miRNA-mediated regulation of NSC fate specification in humans. Furthermore, some 
of these miRNAs were found to exert their regulatory function through the formation 
of regulatory loops with transcription factors (Packer et al., 2008; Zhao et al., 2009). 
Recent studies on the transcription factors PAX6 and SOX2, which are expressed in 
early neuroectodermal cells and NSCs, provided proof that PAX6 and SOX2 function 
as key determinants of human neuroectodermal fate that promote neurogenesis and 
NSC self-renewal respectively (Ring et al., 2012; Zhang et al., 2010c). Hence, the 
aim of this study is to identify miRNAs that directly regulate the expression of PAX6 
or SOX2 to modulate the differentiation of human NSCs along the gliogenic pathway. 
The first step towards our aim of identifying miRNAs that target PAX6 or SOX2 
during the differentiation of NSCs, was to derive NSCs from hESCs as they present a 
viable human model system to make predictions on the molecular mechanisms 
involved in early stages of human neurodevelopment. We set out to derive NSCs 
from hESCs via two different methods – a neurosphere culture method and an 
adherent culture approach involving neural rosette formation. We proceeded further 
to demonstrate a simple and efficient protocol to differentiate NSCs into glial 
progenitor-like cells (GPCs), which are cells supposedly at the early stage of glial 
commitment, and investigated the expression changes of PAX6 and SOX2 during the 
differentiation as well as superficially tested their glioma-tropic property. 
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Comparing the miRNA expression profiles of hESC-derived NSCs and their GPC-
derivative, we searched for miRNAs that have increased expression levels during the 
differentiation to GPCs. We subsequently examined the upregulated miRNAs for their 
PAX6 gene targeting potential. Among the identified miRNAs, miR-145 was recently 
reported to target SOX2 gene in hESCs during differentiation, which led us to 
speculate that it also represses SOX2 in NSCs during glial differentiation (Xu et al., 
2009). Thus, we examined the regulatory function of miR-145 on SOX2 in hESC-
derived NSCs. Our findings, though not conclusive, support the role of miRNAs as 
regulators of key fate determining transcription factors during human neural 
differentiation and warrant further investigation to characterize the miRNA-mediated 




Chapter 2: Materials and Methods 
2.1 Cell culture 
U87, a human glioma cell line, and HeLa, a human cervical cancer cell line, were 
obtained from American Type Culture Collection and cultured in DMEM (Gibco) 
supplemented with 10% FBS (HyClone), L-glutamine (2 mM, Gibco) and 1% 
Pen/Strep (Gibco). Cells were maintained in a 5% CO2 humidified incubator at 37°C. 
H1 hESC line (WiCell, Madison, WI, USA) was cultured in feeder-free conditions 
according to the technical manual “Maintenance of Human Embryonic Stem Cells in 
mTeSRTM1” (STEMCELL Technologies Inc.). In brief, H1 hESCs were maintained on 
BD matrigel hESC-qualified matrix (BD Biosciences) with mTeSRTM1 medium 
(STEMCELL Technologies Inc.) in a 5% CO2 humidified incubator at 37°C. Routinely, 
H1 hESCs were passaged by treatment with dispase (Gibco) followed by mechanical 
scraping every 7 days. Stable H1 hESC clone expressing enhanced green 
fluorescent protein (eGFP) was generated as previously reported (Ramachandra et 
al., 2011) and contributed by Chrishan J.A. Ramachandra. 
ReNcell CX, an immortalized human NSC line derived from human fetal cortical 
tissue, was obtained from Millipore (Billerica, MA, USA). These cells were maintained 
in ReNcell NSC maintenance medium, supplemented with bFGF and EGF (20 ng/ml 
each, PeproTech), on laminin-coated (Sigma-Aldrich) culture plates according to the 
technical manual provided by the manufacturer. 
 
2.2 Generation of NSCs from hESCs 
NSCs were derived from hESC by two different methods: neurosphere suspension 
culture, and neural rosette adherent culture. 
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Neurosphere suspension culture to differentiate hESCs into NSCs was carried out 
according to a published protocol (Reubinoff et al., 2001). Colonies of hESCs were 
first mechanically cut into fragments containing about 150 cells each using a micro-
glass pipette. These fragments were then transferred to untreated polystyrene tissue 
culture dishes (to reduce cell attachment) with NSC medium, comprising DMEM/F12, 
B27 supplement minus vitamin A (1:50), L-glutamine (2 mM), 1% Pen/Strep (all from 
Gibco), and supplemented with 20 ng/ml human recombinant epidermal growth factor 
(EGF, PeproTech) and 20 ng/ml basic fibroblast growth factor (bFGF, PeproTech). 
With half the medium being replaced every 3 to 4 days, the fragments grew in 
suspension into round spheres that were subcultured by dissection into smaller 
pieces using no. 20 surgical blades (Swann-Morton) when their diameter grew 
beyond 500 μm (about every 7 days). Adherent monolayer culture of NSCs was 
obtained from neurospheres at day 28 to 30 of suspension culture for downstream 
differentiation studies by first isolating the neurospheres and then dissociating them. 
Neurospheres were isolated by centrifugation at 150 g for 1 minute to remove the 
supernatant containing dead cells and debris. To obtain a single-cell suspension, 
neurospheres were washed with PBS followed by incubation with Accutase (Gibco) 
for 10 minutes at 37°C and gentle trituration with a 1000 μl pipettor tip. The 
enzymatic action of accutase was neutralized by adding fresh medium and the cell 
suspension was centrifuged for 5 minutes at 300 g. The cells were then resuspended 
in NSC medium and seeded on matrigel-coated plates. Adherent monolayer of 
neurosphere NSCs (NS-NSCs) no later than passage 5 were used in experiments. 
Deriving NSCs from hESCs by neural rosette adherent culture was carried out 
according to a published protocol by Swistowski et al. (2009). Firstly, fragments of 
hESC colonies were harvested by scraping and cultured as embryoid bodies (EBs) in 
untreated tissue culture dishes with EB medium containing DMEM/F12, 
supplemented with 20% KnockOutTM Serum Replacement, 2 mM L-glutamine, 0.1 
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mM β-mercaptoethanol, non-essential amino acids (NEAA, 1:100) and 1% Pen/Strep 
(all from Gibco). Medium change was performed every other day for 8 days. EBs 
were then cultured for 2 days in suspension in neural induction medium, containing 
DMEM/F12 supplemented with N2 supplement (1:100), 2 mM L-glutamine, 0.1 mM 
NEAA, 1% Pen/Strep (all from Gibco), and 20 ng/ml bFGF (PeproTech), and were 
subsequently seeded onto cell culture plates coated with CELLstartTM (Gibco) for 
attachment. Several neural rosettes formed 3 to 5 days after adherent culture. These 
rosettes were isolated manually using a micro-glass pipette and dissociated into 
single cells by treatment with Accutase (Gibco) for 5 minutes at 37°C and gentle 
trituration with a 1000 μl pipettor tip. Accutase was neutralized by adding fresh 
medium and removed after centrifuging the cells for 5 minutes at 300 g. The cells 
were then replated on CELLstartTM-coated culture plates and expanded in neural 
expansion medium comprising Neurobasal medium supplemented with NEAA 
(1:100), B27 supplement minus vitamin A (1:50), 2 mM L-glutamine, 1% Pen/Strep 
(all from Gibco), 20 ng/ml bFGF (PeproTech) and 10 ng/ml recombinant human 
leukemia inhibitory factor (LIF, Millipore). Adherent cultures of rosette NSCs (R-NSCs) 
no later than passage 5 were used in experiments. 
 
2.3 Generation of GPCs from hESC-derived NSCs 
NSCs were further differentiated into GPCs using a protocol adapted from published 
methods to generate oligodendroglial or oligodendrocyte-type-2-astrocyte (O-2A) 
progenitors (Kang et al., 2007; Neri et al., 2010; Rao et al., 2009). Adherent cultures 
of GPCs were generated by exposing NSCs (either NS-NSCs on matrigel or R-NSCs 
on CELLstart) to GPC medium containing DMEM/F12, B27 supplement minus 
vitamin A (1:50), L-glutamine (2 mM), 1% Pen/Strep (all from Gibco), and 
supplemented with 20 ng/ml bFGF (PeproTech) and 20 ng/ml platelet-derived growth 




2.4 Terminal differentiation of hESC-derived NSCs into glial 
cells and neurons 
To assess the multipotency of hESC-derived NSCs, NSCs were differentiated into 
glial cells and neurons according to a published protocol (Swistowski et al., 2010). 
NSCs were differentiated into glial cells by culturing in DMEM/F12 supplemented with 
2 mM L-glutamine, NEAA (1:100), B27 supplement (1:50) and N2 supplement (1:100, 
all from Gibco) for 14 days after which they were fixed for immunostaining. 
Neuronal differentiation of NSCs was initiated by seeding NSCs onto culture plates 
coated with poly-D-lysine (10 μg/ml, Sigma-Aldrich) and laminin (10 μg/ml, Sigma-
Aldrich) and exposing them to Neurobasal medium supplemented with NEAA (1:100), 
2 mM L-glutamine, 200 ng/ml recombinant human sonic hedgehog (Shh, PeproTech) 
and 100 ng/ml FGF8 (PeproTech). After 10 days, Shh and FGF8 were substituted 
with 20 ng/ml brain-derived neurotrophic factor (BDNF, PeproTech), 20 ng/ml glial 
cell-derived nerve factor (GDNF, PeproTech), 1 μM transforming growth factor beta 3 
(TGF-β3, PeproTech) and 1 mM dibutyryl cyclic adenosine (dcAMP; Sigma-Aldrich), 
and the cells were cultured in this medium for an additional three weeks before 
processing for immunostaining. 
 
2.5 Immunocytochemistry 
Cells were fixed with 4% paraformaldehyde for 15 minutes, permeabilized with 0.3% 
Triton X-100 in PBS for 5 minutes, blocked with 5% bovine serum albumin (BSA) in 
PBS for 1 hour and incubated with primary antibody diluted in 1% BSA/PBS 
overnight at 4°C. The next day, cells were washed thrice with PBS and incubated 
with the appropriate secondary antibody for 1 hour at room temperature in the dark. 
Secondary antibodies were tested for non-specific immunoreactivity. Following the 
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incubation with secondary antibodies, cells were washed with PBS and nuclei were 
stained with Hoechst 33342 (Invitrogen) for 1 minute before a final wash with PBS. 
Primary antibodies used include: rabbit anti-glial fibrillary acidic protein (GFAP, 1:200, 
G4546, Sigma-Aldrich); mouse anti-βIII tubulin (1:200, G712A, Promega); rabbit anti-
SOX2 (1:100, NBP1-40712, Novus Biologicals); and secondary antibodies used were 
NorthernLights 557 conjugated anti-rabbit IgG (1:200, R&D Systems) and Texas 
Red-conjugated anti-mouse (1:200, Abcam). Cells were imaged using an Olympus 
fluorescence microscope. 
 
2.6 RNA isolation 
Total RNA from cells in adherent culture, cell pellets or neurospheres was extracted 
by TRIzol (Invitrogen) and subjected to DNase treatment with the TURBO DNA-free 
kit (Ambion) to remove traces of contaminating genomic DNA. In general, 10 μg of 
total RNA was treated with 1 μl or 2 units of TURBO DNase in 50 μl for 30 minutes at 
37°C, followed by a second round of treatment with 1 μl of TURBO DNase for 
another 30 minutes at 37°C. 
 
2.7 Reverse transcriptase-PCR and Quantitative RT-PCR of 
mRNA 
Complementary DNA (cDNA) was synthesized from 500 ng of DNase-treated total 
RNA using the SuperScript III First-Strand Synthesis System (Invitrogen) with 
oligo(dT) primers as directed by the manufacturer. 
For RT-PCR, specific sequences in the resultant cDNA mixture were amplified by 
PCR using 2ൈ PCR Master Mix (Fermentas) and primer sets listed in Table 2.1 with 
the following conditions: initial denaturation step at 95°C for 3 minutes followed by 30 
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cycles of 95°C for 30 seconds, 55°C for 30 seconds, and 72°C for 60 seconds, and 
finishing with a final extension step at 72°C for 5 minutes. PCR products were 
resolved on 2% agarose gels and visualized by SYBR Safe DNA gel stain 
(Invitrogen). 
For real-time qRT-PCR, PCR was performed using 1:100 diluted cDNA mixed with 
0.3 μM of each primer and iQ SYBR Green Supermix (Bio-Rad) in a 25-μl reaction. 
PCR amplification and real-time measurement were performed in the iCycler iQ5 
system (Bio-Rad). Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used 
as an endogenous control. Relative expression of target mRNA was normalized to 
GAPDH and analyzed by the 2−∆∆Ct method (Livak and Schmittgen, 2001). Primer 
sequences used for RT-PCR and qRT-PCR are listed in Table 2.1. All reactions were 
run in triplicates. 
1Table 2.1 List of primers used in RT-PCR and qRT-PCR of mRNA 
Table 2.1 List of primers used in RT-PCR and qRT-PCR of mRNA 
β-actin 
 Forward: GCCCAGAGCAAGAGAGGCAT 
 Reverse: GGCCATCTCTTGCTCGAAGT 
 
eGFP 
 Forward: AGCCGCTACCCCGACCACAT 
 Reverse: CGTCGCCGATGGGGGTGTTC 
 
GAPDH 
 Forward: TTGACGCTGGGGCTGGCATT 
 Reverse: GTGCTCTTGCTGGGGCTGGT 
 
Musashi1 
 Forward: GGCCGAGCCCCTGGAACCAT 
 Reverse: CAGTGTCGCTGGGCAAGCCC 
 
Nestin 
 Forward: GAAACAGCCATAGAGGGCAAA 
 Reverse: TGGTTTTCCAGAGTCTTCAGTGA 
 
NG2 
 Forward: CACGGCTCTGACCGACATAG 
 Reverse: CCCAGCCCTCTACGACAGT 
 
OCT4 
 Forward: CGTGAAGCTGGAGAAGGAGAAGCTG 
 Reverse: AAGGGCCGCAGCTTACACATGTTC 
  
PAX6 
 Forward: AACAGACACAGCCCTCACAAACA 
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 Reverse: CGGGAACTTGAACTGGAACTGAC 
 
PDGFR 
 Forward: GAAGCTGTCAACCTGCATGA 
 Reverse: CTTCCTTAGCACGGATCAGC 
 
SOX1 
 Forward: CAATGCGGGGAGGAGAAGTC 
 Reverse: CTCCTCTGGACCAAACTGTG 
 
SOX2 
 Forward: TGGACAGTTACGCGCACAT 
 Reverse: CGAGTAGGACATGCTGTAGGT 
 
 
2.8 Flow cytometry 
Flow cytometry was utilized to analyze the morphology of cells, the expression of 
fluorescent reporter genes and the expression of surface markers. For flow 
cytometric analysis of surface marker expression, cells were resuspended in PBS 
with 5% FBS and incubated for 20 minutes at 4°C in the dark with phycoerythrin 
(PE)-conjugated or allophycocyanin (APC)-conjugated monoclonal antibodies. 
Monoclonal antibodies used include PE-conjugated anti-NG2 (FAB2585P, R&D 
Systems), anti-CD140a (anti-PDGFR, 556002, BD Pharmingen), anti-A2B5 (130-
093-581, Miltenyi Biotec), and APC-conjugated anti-NG2 (FAB2585A, R&D Systems), 
anti-A2B5 (130-093-582, Miltenyi Biotec), along with their respective isotype controls. 
The stained cells were washed, resuspended in 1 ml of PBS with 5% FBS and 
analyzed with a BD FACSCaliburTM flow cytometer and CellQuest software (BD 
Biosciences). For two-color flow cytometric analysis, PE and APC-conjugated 
antibody pairs were used to stain the cells to reduce the need to compensate for 
overlapping emission spectra. 
 
2.9 Western blot analysis 
Cell lysates were obtained from cells using CelLytic M mammalian cell 
lysis/extraction reagent (Sigma-Aldrich) supplemented with protease inhibitor cocktail 
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(1:50, Sigma-Aldrich) as directed by the manufacturer. Cells were lysed 72 hours 
after transfection for all transfection experiments, and 48 hours after transduction for 
all baculovirus transduction experiments. Protein concentration in the cell lysates was 
estimated using the DC protein assay (Bio-rad). Protein samples were mixed with 
NuPAGE LDS sample buffer (1:4, Novex) and NuPAGE reducing agent (1:10, 
Novex), heated at 70°C for 10 minutes, separated on 4-12% NuPAGE Bis-Tris 
denaturing gels with morpholineethanesulfonic acid (MES) running buffer, and 
eventually transferred to nitrocellulose membranes using the iBlot dry blotting system 
(Invitrogen). Membranes were blocked with 5% BSA in Tris buffered saline with 0.1% 
Tween 20 (TBST) for 1 hour and incubated overnight at 4°C with primary antibody. 
Primary antibodies used for Western blotting include rabbit anti-PAX6 (1:500, 
H00005080-D01P, Abnova), rabbit anti-SOX2 (1:10,000, NBP1-40712, Novus 
Biologicals), rabbit anti-β-actin (1:2,000, 4970, Cell Signaling Technology) and 
mouse anti-GAPDH (1:1,000, ab9484, Abcam). After three washes of 5 minutes each 
with TBST, membranes were incubated for 1 hour with horseradish peroxidase 
(HRP)-conjugated anti-rabbit or anti-mouse secondary antibody (1:10,000, GE 
Healthcare), and followed by another round of washing with TBST. 
Chemiluminescent detection was performed using Amersham ECL Prime detection 
reagent (GE Healthcare) and protein bands were visualized on X-ray film or with the 
VersaDocTM imaging system (Bio-Rad). After visualization of the target gene, 
membranes were stripped of antibodies with Restore Western Blot Stripping Buffer 
(Pierce) and reprobed using anti-β-actin or anti-GAPDH antibodies for loading control. 
Protein band intensities were quantified using the NIH ImageJ software with signal 





2.10 In vitro migration assay 
The migration ability of eGFP-hESC-derived GPCs was determined by a modified 
Boyden chamber assay using the BD FalconTM HTS FluoroBlokTM polyethylene 
terephthalate membrane 24-well cell culture inserts with 8.0 μm pores (BD 
Biosciences). U87 cells were seeded in a 24-well culture plate at a density of 2ൈ105 
cells per well and maintained in unsupplemented Opti-MEM (Gibco) for 24 hours. 
EGFP-GPCs were then seeded in the cell culture inserts at a density of 5ൈ104 cells 
in 200 μl of Opti-MEM per insert. One insert was placed into each well of the 24-well 
plate containing U87 cells in 800 μl of Opti-MEM and maintained together in a 5% 
CO2 humidified incubator at 37°C. After 24 hours, transmigrated cells were manually 
counted from five imaged fields (fluorescent field, 20ൈ  magnification). Migration 
activity was calculated as the mean number of cells per field and expressed as fold-
increase relative to the control. Migration of eGFP-GPCs towards Opti-MEM alone 
was used as control and treatment/control groups consisted of five independent 
repeats each. 
 
2.11 MicroRNA microarray 
Small RNAs were isolated from 5 μg of total RNA using PureLinkTM miRNA Isolation 
Kit (Ambion) and labeled with using the NCodeTM miRNA Rapid Labeling System 
(Invitrogen) according the manufacturer’s instructions. Briefly, poly(A) tails were 
added to the small RNAs and DNA polymer labeled with multiple Alexa Fluor dye 
molecules were ligated to the tailed RNAs via an oligo(dT) bridge. We used a two-
color labeling experimental design in which small RNAs from neurosphere NSCs 
were labeled with Alexa Fluor-3 and small RNAs from GPCs derived from 
neurosphere NSCs (NS-GPC) at day 5 post-differentiation were labeled with Alexa 
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Fluor-5. The two differentially labeled RNA samples were combined together and the 
volume was reduced to approximately 25 μl using an Eppendorf Concentrator. The 
labeled sample mixtures were hybridized overnight to NCodeTM Human miRNA 
Microarray V3 (Invitrogen), which contains optimized probes for 710 human miRNAs 
catalogued in the miRBase Sequence Database, release 10.0 
(http://microrna.sanger.ac.uk/) and processed as directed by the manufacturer. 
Microarray slides were scanned using an Agilent DNA Microarray Scanner (Agilent 
Technologies) and the intensity data were acquired and analyzed using the GenePix 
Pro 6.0 software (Molecular Devices). Image intensities were measured as median of 
foreground intensities with background correction and normalization to Alexa Fluor 
Dye Control probes. To obtain reliable data, each data file was “Flag” filtered, and 
absent or artifactual spots were manually excluded from the data set. Data sets for 
biological triplicate slides of neurosphere NSC versus NS-GPC were then grouped 
and averaged. To identify differentially expressed miRNAs between NSCs and GPCs, 
the fold-change minimum cutoff was set at 2-folds. 
 
2.12 MicroRNA target prediction 
Transcripts for PAX6 (variants 1–3) and SOX2 were retrieved from the NCBI 
Nucleotide Database and screened for binding sites of miRNAs selected from the 
miRNA microarray using RNA22 (Miranda et al., 2006) or RNAhybrid (Rehmsmeier 
et al., 2004). Parameters for RNA22 target prediction was set to allow a maximum of 
1 unpaired base within the extent of the seed region of 6 nucleotides, with G:U 
wobble base pairing permitted, and specified for a minimum of 10 paired-up bases in 




2.13 Quantitative RT-PCR of miRNA 
Real-time quantitative PCR of miRNA was performed as described by Choudhury et 
al. (2012). Firstly, poly(A) tails were added to 1–2 μg of DNase-treated total RNA with 
the Poly(A) Tailing Kit (Ambion) using 1 μl of poly(A) polymerase (PAP) in a 25 μl 
reaction. Subsequently, the poly(A)-tailed small RNA fraction was enriched and 
purified with the RNeasy Mini Kit (Qiagen) following a modified cleanup protocol to 
retain small RNA species. This was followed by reverse transcription of the purified 
polyadenylated small RNAs using the SuperScript III First-Strand Synthesis System 
(Invitrogen) with the following poly(T) adaptor sequence: 5’-
CGATAGCGACGATACAGACTTGTCACTATAGG(T)12VN-3’ (V: A/G/C, N: A/G/C/T). 
The real-time PCR for quantification of miRNA was performed using the protocol 
described for qRT-PCR of mRNA (Section 2.7). 5S ribosomal RNA (rRNA) was used 
as the endogenous control. Relative expression of target miRNA was normalized to 
5S rRNA and analyzed by the 2−∆∆Ct method. The reverse primer used was: 5’-
CGATAGCGACGATACAGACTTGTCAC-3’. The forward primers used were based 
on full-length mature miRNA sequences and are listed in Table 2.2. 
 
2Table 2.2 List of forward primers used in qRT-PCR of miRNA 




















5S rRNA 5’-CCGCCTGGGAATACCGGGTGCTGTAGGCTTT-3’ 
 
 
2.14 miRNA mimics, miRNA expression vectors and 
transfection 
miRIDIANTM miRNA Mimics, which are duplex RNA oligonucleotides that mimic 
mature miRNA function, for miR-21, -22, -145 and -221, and miRIDIANTM miRNA 
Hairpin Inhibitor, which are single-stranded oligonucleotides that inhibit mature 
miRNA function, against miR-22 were purchased from Dharmacon. For Western blot 
experiments, miRIDIANTM miRNA Mimic Negative Control #1 and #2 (Dharmacon) 
were used as control miRNA. For luciferase reporter assays, miRNA Mimic Negative 
Control #2 and miRNA Hairpin Inhibitor Negative Control #2 (Dharmacon) were used 
as control miRNA and inhibitor respectively. miRIDIANTM miRNA Mimic Transfection 
Control with Dy547 from Dharmacon was used as a transfection control to monitor 
transfection efficiency. 
For miRNA over-expression, the constructs miExpressTM Precursor microRNA pEZX-
MR04 containing precursor sequence of hsa-miR-145 (pEZX-miR-145, HmiR0085-
MR04) or a scrambled miRNA sequence (pEZX-miR-scr, CmiR0001-MR04) with 
eGFP reporter gene were purchased from GeneCopoeia. For miRNA inhibition, the 
miArrestTM microRNA Inhibitor vector pEZX-AN01 expressing miR-145-specific 
inhibitor (pEZX-anti-miR-145, HmiR-AN0192-AM01) or inhibitor control (pEZX-Inh 
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Ctrl, CmiR-AN0001-AM01) with mCherry as the reporter gene were purchased from 
GeneCopoeia. The pEZX-anti-miR-145 construct encodes for a miR-145-specific 
decoy target that hybridizes with and traps two molecules of the target miRNA, while 
the pEZX-Inh Ctrl construct expresses a scrambled, non-specific miRNA decoy 
sequence. 
miRNA mimics and hairpin inhibitors from Dharmacon were transfected at a 
concentration of 10–20 nM into HeLa cells using Lipofectamine 2000 (Invitrogen) and 
into ReNcell NSCs using X-tremeGENE HP DNA Transfection Reagent (Roche 
Applied Science). At 48 or 72 hours post-transfection, cells were imaged or lysed for 
protein isolation. Pre-miRNA and miRNA inhibitor expression vectors (2 μg DNA per 
well of a 6-well plate) were transfected into ReNcell NSCs using X-tremeGENE HP 
transfection reagent. Among several transfection reagents that were tested for 
transfection of ReNcell NSCs, such as Lipofectamine 2000, Lipofectamine RNAiMax, 
FuGENE HD and X-tremeGENE 9, X-tremeGENE HP had the highest transfection 
efficiency with low cytotoxicity among those tested and was chosen for use. All 
transfection experiments were carried out using medium without Pen/Strep. 
 
2.15 Luciferase reporter assay 
The pMIR-REPORTTM Luciferase vector, which encodes for firefly luciferase under 
the control of a CMV promoter, was purchased from Ambion along with the pMIR-
REPORTTM β-galactosidase Control Plasmid (pCMV-β-gal), which provides 
constitutive expression of β-galactosidase and was used for transfection 
normalization. The pMIR-pax6-1.9k, pMIR-pax6-3.4k and pMIR-pax6-4k luciferase 
reporter vectors were constructed by cloning the corresponding PAX6 3’UTR 
fragments (pax6-1.9k, pax6-3.4k and pax6-4k) into the multiple cloning site (MCS) 
downstream of the luciferase coding sequence in the pMIR-REPORTTM Luciferase 
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vector (Ambion). All three PAX6 3’UTR fragments were amplified from cDNA 
synthesized from total RNA of ReNcell NSCs using the primers listed in Table 2.3 
and ligated into the MluI–PmeI sites of the pMIR-REPORT vector. 
Table 2.3 List of primers used for amplifying fragments of PAX6 3’ UTR.  
pax6-1.9k Size: 3279 bp Restriction enzymes: MluI/PmeI 
 Forward: GACACGCGTCTGTTAGAGCCGCTTCAGTTC 
 Reverse: GACGTTTAAACCTAGTATGAGAGGCCCAGAGTAAA 
 
pax6-3.4k Size: 2218 bp Restriction enzymes: MluI/PmeI 
 Forward: GACACGCGTGAATAATGAGCACAGACACATCAAC 
 Reverse: GACGTTTAAACTATTCCTTATGTCCACCTCCAG 
 
pax6-4k Size: 2941 bp Restriction enzymes: MluI/PmeI 
 Forward: GACACGCGTCTGCACATTTGGAGACACCTT 
 Reverse: GACGTTTAAACTGTATACAGCTTTTATTCAGAATTAGAATAATTG 
(Underlined sequences denote restriction enzyme sites for cloning.) 
3Table 2.3 List of primers used for amplifying fragments of PAX6 3’ UTR 
 
HeLa cells in 96-well plates were co-transfected with 30 ng of pCMV-β-gal, 30 ng of 
either pMIR-pax6-1.9k, pMIR-pax6-3.4k or pMIR-pax6-4k and 20 nM of miRNA 
mimics using Lipofectamine 2000. For the experimental design where miRNA mimics 
were co-transfected with miRNA hairpin inhibitors along with the reporter constructs, 
10 nM each of mimic and hairpin inhibitor was used. miRNA Mimic Negative Control 
#2 and miRNA Hairpin Inhibitor Negative Control #2 from Dharmacon were used as 
miRNA mimic and inhibitor controls respectively. At 48 hours after transfection, cells 
were lysed using Luciferase Cell Culture Lysis Reagent (Promega), and luciferase 
and β-galactosidase activities in the same lysate were assayed using the Luciferase 
Assay System (Promega) and β-Galactosidase Enzyme Assay System (Promega) 
respectively. For each sample lysate, luciferase activity was normalized to β-
galactosidase activity. For each sample group, data was obtained from a minimum of 




2.16 Baculovirus preparation and transduction 
Recombinant baculovirus was produced and propagated using the Bac-to-Bac 
Baculovirus Expression System (Invitrogen). Baculoviral vectors expressing 
precursor miR-145 or miR-145-specific inhibitor, or the corresponding scrambled 
controls, were constructed by first cloning the precursor miRNA or miRNA inhibitor 
expression cassettes from the miExpressTM Precursor microRNA or miArrestTM 
microRNA Inhibitor vectors (Genecopoeia) into the pFastBac1 shuttle vector 
(Invitrogen). The pre-miR-145 and scrambled control expression cassettes with 
eGFP reporter were excised out from the plasmids pEZX-miR-145 and pEZX-miR-scr, 
respectively, and cloned into separate pFastBac1 plasmids using SpeI/XhoI. The 
anti-miR-145 and inhibitor control expression cassettes with mCherry as the reporter 
were excised out from pEZX-anti-miR-145 and pEZX-Inh Ctrl, respectively, and 
cloned into separate pFastBac1 plasmids, modified to contain an NsiI restriction site 
in the MCS, using NsiI/EcoRI. The expression cassettes in the recombinant 
pFastBac constucts were then inserted into bacmids by Tn7-mediated transposition 
in DH10Bac E. coli cells. The recombinant bacmids were in turn transfected into Sf9 
insect cells to produce baculovirus. Sf9 cells were cultured in Sf-900 II SFM 
(Invitrogen) at 27°C. High-titre virus stocks were produced according to the Bac-to-
Bac Baculovirus Expression System protocol (Invitrogen). Baculoviral particles were 
concentrated by centrifugation at 28,000 g for 60 minutes at 4°C and resuspended in 
PBS prior to use in transduction experiments. The generated recombinant baculoviral 
vectors expressing precursor miR-145, miRNA scrambled control, miR-145 inhibitor 
or inhibitor control were BV-miR-145, BV-miR-scr, BV-anti-miR-145 and BV-Inh Ctrl, 
respectively. 
Baculoviral titres were determined by plaque assay on Sf9 cells and by qRT-PCR 
according to published protocols (Hitchman et al., 2007). For plaque assay, 1 ml of 
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10-3 to 10-8 dilutions of baculovirus supernatant in Sf-900 II SFM was added to each 
well of Sf9 cells in 6-well plates at 50% confluence. Following an hour of incubation 
at room temperature, the virus containing medium was removed and Sf9 cells were 
overlaid with 1% nutrient agarose and incubated at 27°C. After 7 days, plaques that 
formed were counted. For titration of viral particles by qRT-PCR, viral genomic DNA 
was isolated from 200 μl of virus supernatant using the High Pure Viral Nucleic Acid 
Kit (Roche Applied Science) as directed by the manufacturer. qRT-PCR was carried 
out with each 25-μl reaction containing iQ Supermix (Bio-Rad), 100 nM of forward 
primer (5’-AAAGCAACCTCATAACCACCATG-3’), 100 nM of reverse primer (5'-
CCAATTCGCCTTCAGCCATG-3’) and 100 nM of Taqman probe (6-FAM-5’-
CAGACTGGTGCCGACGCCGCC-3’-BHQ1) to detect the gp64 gene, which encodes 
for a major baculoviral envelope glycoprotein. PCR amplification and detection was 
carried out with the iCycler iQ5 system (Bio-Rad). For each PCR run, five ten-fold 
dilutions of known concentrations (103 to 108 copies) of the standard viral gp64 DNA 
was used to establish a standard curve, which was used for estimating viral particle 
titres. 
ReNcell NSCs and R-NSCs were transduced with baculovirus at a multiplicity of 
infection (MOI) of 50. For co-transduction, R-NSCs were infected with combinations 
of BV-miR-145 or BV-miR-scr, and BV-anti-miR-145 or BV-Inh Ctrl an MOI of 25 for 
each vector. Cells were transduced at the time of seeding on culture plates and 
cultured overnight with the virus particles. Medium was changed the next day to 
remove the virus particles. At 48 hours post-transduction, cells were imaged or lysed 




2.17 Statistical analysis 
Data are presented as mean ± SD unless otherwise indicated. Differences between 
sample groups were analysed by unpaired Student’s t-test. A two-tailed p-value of 




Chapter 3: Derivation of neural progenitors from 
hESCs 
3.1 Introduction and aims 
3.1.1 Deriving NSCs 
Human ESCs present a renewable source of NSCs for potential application in 
regenerative medicine and as a feasible model to study the underlying mechanisms 
regulating NSC self-renewal and differentiation in humans. Over the years numerous 
protocols detailing the derivation of expandable NSC populations have been 
developed (Chambers et al., 2009; Dhara and Stice, 2008; Reubinoff et al., 2001; 
Swistowski et al., 2009). Often, improved protocols to derive neural cells from hESCs 
are developed based on, and in parallel with, new insights in developmental 
neurobiology. In general, there are two main approaches to derive and maintain 
NSCs in vitro, via a neurosphere suspension culture or an adherent monolayer 
culture. Early efforts to isolate NSCs from the CNS or derive NSCs from ESCs 
depended on neurosphere cultures (Reubinoff et al., 2001). More recent 
developments in adherent monolayer culture methods involve the formation of neural 
rosettes from which multipotent NSCs can be derived (Elkabetz et al., 2008; Gerrard 
et al., 2005; Wilson and Stice, 2006; Zhang et al., 2001). Neural rosettes are radial 
arrangements of columnar cells that bear characteristics of neuroepithelial cells in the 
neural tube. Neuroepithelial cells are regarded to be early NSCs that form during 
embryonic development of the neural tube as they show potential to generate all 
neuronal and glial subtypes in vivo (Wilson and Stice, 2006). Therefore, in this 
chapter we demonstrate the derivation of NSCs from hESCs using two different 
methods, a neurosphere culture approach and a neural rosette adherent culture. 
These derivation methods employ the external application of growth factors and 
cytokines to ‘instruct’ the specification of hESCs into neuroectodermal lineage, and 
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for the maintenance of NSCs in in vitro cultures. Growth factors bFGF and EGF are 
routinely used to enrich primary cultures of NSCs and for derivation of NSCs from 
ESCs (Gritti et al., 1999; Reubinoff et al., 2001; Vescovi et al., 1999). The long-term 
expansion of NSC cultures involves promoting symmetric over asymmetric divisions 
while keeping commitment in abeyance, an effect mediated to some extent by the 
combination of bFGF and EGF (Conti et al., 2005). As mentioned earlier in Section 
1.2.2 of this thesis, the cytokine LIF has also been found to be essential for 
expansion and maintenance of NSC cultures and is used in combination with bFGF 
or EGF for culturing NSCs in more recent protocols, including the neural rosette 
adherent culture described here (Shin et al., 2006; Swistowski et al., 2009; Wright et 
al., 2003). 
 
3.1.2 Deriving GPCs 
Whilst many transplantation studies have been focused on NSCs, NSC derivatives 
like glial progenitor cells (GPCs) are gaining attention as promising therapeutic 
agents to treat demyelinating disorders, including spinal cord injury (Goldman et al., 
2012). GPCs, also referred to as oligodendroglial or oligodendrocyte-type-2 astrocyte 
(O-2A) progenitors/precursors, are not distinctly localized in the CNS but are instead 
found throughout in both gray and white matter, and constitute about 3% of cells in 
the adult human forebrain (Roy et al., 1999). Generally regarded as more restricted 
transit-amplifying derivatives of NSCs, they can give rise to the two major classes of 
macroglial cells, namely astrocytes and oligodendrocytes, in the context of the CNS. 
Nevertheless, there are studies reporting that GPCs may be reverted back to a more 
uncommitted, multipotential neurogenic progenitor in vitro when exposed to certain 
mitogens (Nunes et al., 2003). 
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Human GPCs can be isolated and purified from fetal and adult brain tissue using a 
number of surface antigens. They were first isolated based on their selective 
expression of A2B5, a cell surface ganglioside epitope (Roy et al., 1999). However, 
the A2B5 surface marker was also reported to be occasionally expressed by 
committed astrocytes and cells of neuronal lineage (Dietrich et al., 2002; Sim et al., 
2011). Subsequently, GPC were broadly regarded as cells expressing the chondroitin 
sulfate proteoglycan, NG2 (Belachew et al., 2003; Nishiyama et al., 2009). Recent 
studies further demonstrated that the subpopulation of NG2-positive GPCs that co-
expresses PDGF receptor  (PDGFR) had greater myelinogenic potential than the 
population of GPCs sorted based on A2B5, thus refining the selection criteria for 
myelinogenic GPCs (Sim et al., 2011). Fetal and adult human GPCs isolated using 
the above-mentioned markers have shown great potential to produce myelinogenic 
oligodendrocytes upon transplantation in rodent models of myelin disorders and were 
the most effective progenitor population in improving locomotor and sensory recovery 
in spinal cord injury (Alexanian et al., 2011; Windrem et al., 2002). Furthermore, 
GPCs have been derived from mouse and human pluripotent stem cells, including 
iPS cells, and their promising ameliorative potential was demonstrated by 
transplantation into demyelination animal models (Brüstle et al., 1999; Kang et al., 
2007; Keirstead et al., 2005; Neri et al., 2010; Rao et al., 2009). However, most of 
these protocols involved complicated steps, use of multiple growth factors or a 
lengthy derivation process. Hence, in this study we demonstrate the derivation of 
GPCs from hESC-derived NSCs via a facile protocol that utilizes just two growth 
factors, bFGF and PDGF-AA (the A-chain homodimeric PDGF). 
Transplantation studies have shown that engrafted GPCs exhibit high migratory 
ability to infiltrate and integrate into injury sites (Sim et al., 2011; Windrem et al., 
2002). Furthermore, this migration competence appeared to specifically target injury 
sites without extending into normal tissue (Windrem et al., 2002). Therefore, it is 
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postulated that GPCs could potentially be used as novel gene delivery vehicles to 
target tumor cells for cancer gene therapy, and so we examined the in vitro tumor 
tropic properties of GPCs derived from genetically modified hESCs expressing eGFP. 
 
3.2 Results 
3.2.1 NSCs derived from hESCs via neurosphere culture display 
neuroectodermal identity 
Neurosphere assays and culture methods have widely been used to isolate and 
propagate NSCs and progenitors from fetal and adult brain tissue, as well as to 
establish NSC cultures from ESCs (Jensen and Parmar, 2006; Tropepe et al., 2001). 
We derived NSCs from H1 hESCs (Figure 3.1A) via a neurosphere culture method 
reported by Reubinoff et al. (2001). H1 hESCs formed free-floating spherical 
aggregates, which we termed ‘neurospheres’, in NSC medium containing bFGF and 
EGF, and their sizes typically ranged from 50 to 300 µm (Figure 3.1B). The NSC 
characteristics of our hESC-derived neurosphere NSCs were demonstrated by their 
functional capacity to differentiate into neuronal and glial progeny. hESC-derived 
neurospheres were enzymatically dissociated and cultured as adherent monolayer 
(Figure 3.1C) on matrigel or laminin prior to differentiation into glial cells and neurons. 
Differentiation into neurons and glial cells was performed according to the protocol 
reported by Swistowski et al. (2009). Immunostaining of the differentiated cells for β-
III tubulin, a microtubule subunit exclusively expressed in neurons of higher 
vertebrates (Burgoyne et al., 1988), and for GFAP, an intermediate filament protein 
characteristically expressed by astrocytes of the CNS (Pekny and Pekna, 2004), 
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Figure 3.1 Cells from neurospheres derived from hESC show cellular 
characteristics of NSCs. (A–C) Generation of NSCs from hESC via neurosphere culture. 
(A) hESC line H1 (inset photo shows typical morphology) cultured on matrigel-coated 
plates in mTeSR1 medium was used to generate NSCs. (B) Free-floating hESC-derived 
neurospheres after 30 days in NSC medium. (C) Plated NSCs from enzymatically-
dissociated neurospheres were maintained in NSC medium on matrigel. (D) GPCs at 
passage 5 following in vitro differentiation of hESC-derived NSCs by treatment with GPC 
medium for 14 days. (E–F) Differentiation of NSCs from hESC-derived neurospheres into 
neuronal (E) and glial (F) cells as shown by immunocytochemistry with antibodies against 
β-III tubulin (TuJ1) and glial fibillary acidic protein (GFAP), respectively. (i) β-III tubulin or 
GFAP immunostaining; (ii) Nuclei were stained with Hoechst 33342 (blue); (iii) phase 
contrast. Scale bar: 50 µm. 




Furthermore, the expression of genes characteristic of NSCs were analyzed by RT-
PCR. The results shown in Figure 3.2A confirmed that neuroectodermal genes, 
SOX1, PAX6, Nestin, and Musashi1, which are expressed by self-renewing and 
multipotent neuroepithelial cells and are routinely used as NSC markers (Kalyani et 
al., 1997; Kaneko et al., 2000; Lendahl et al., 1990), were upregulated or turned-on. 
The expression of SOX2, a hESC and NSC marker, was maintained, while the ESC-
specific gene OCT4 was shut-down in hESC-derived neurospheres 30 days after 
differentiation from hESCs in suspension culture. While none of these markers per se, 
used here to identify hESC-derived NSCs, are definitive for NSCs, the collective 
expression of a number of these early neuroectodermal markers suggest that the 
hESC-derived spheres contain cells bearing the molecular identity of NSCs. 
Moreover, cells from hESC-derived neurosphere even when dissociated and cultured 
as adherent monolayer (termed as NS-NSC) could retain the molecular identity of 
NSCs and expressed the NSC genes, SOX1, PAX6, Nestin, and Musashi1, for a 
certain number of passages in NSC medium (Figure 3.2B). ReNcell NSCs, which 
are immortalized human NSCs and represent in a broad sense the native NSC in the 
human brain, was used as a positive control for expression of neuroectodermal 
genes. The RT-PCR reactions where reverse transcriptase was omitted resulted in 
no PCR product, thus excluding the possibility of genomic DNA contamination. 
Therefore, the results indicate that neurosphere culture provides a facile approach to 
derive NSCs from hESCs and for prolong maintenance of NSCs in vitro, usually for 
up to 16 weeks (data not included here) (Reubinoff et al., 2001). Nevertheless, for 
the purpose of consistency in our experiments neurospheres were used at day 30 of 






























Figure 3.2 Cells from neurospheres derived from hESC express neuroectodermal 
markers. (A–B) RT-PCR analysis showed that hESC pluripotency marker OCT4 is 
downregulated, whereas neuroectodermal markers (PAX6, SOX1, Nestin and Musashi1) 
are upregulated or turned on in neurospheres (NS) cultured in NSC medium for 30 days 
(A) and in neurosphere NSCs (NS-NSCs) that were cultured for 2 passages as adherent 
culture on matrigel-coated plates in NSC medium after neurosphere dissociation into single 
cells (B). SOX2, a hESC and NSC marker, was detected in H1, H1-derived neurospheres 
and NS-NSCs at passage 2. ReNcell (ReN), an immortalized human NSC line, served as a 
positive control for expression of the neuroectodermal markers. Actin served as loading 
control. (+: with reverse transcriptase; –: without reverse transcriptase) 




3.2.2 NSCs derived from hESCs via neural rosette formation display 
neuroectodermal identity 
NSCs were also derived from H1 hESCs via an adherent culture method involving 
the formation and isolation of neural rosettes (Swistowski et al., 2009). This method 
involved the generation of EBs which were plated and exposed to medium containing 
bFGF to induce the cells towards the neural lineage. Neural rosettes (Figure 3.3A) 
were generated on average within 2 weeks from the start of EB culture of hESCs. 
These rosettes were manually isolated, dissociated and maintained as adherent 
culture on CELLstart (Figure 3.3B) in neural expansion medium that contains the 
combination of bFGF and LIF, which promotes expansion of NSCs (Galli et al., 2000; 
Wright et al., 2003). These cells in adherent culture, which we refer to as rosette-
NSCs (R-NSCs), expressed the neuroectodermal markers, PAX6, SOX2, SOX1, and 
Nestin, at similar levels to hESC-derived neurospheres as determined by RT-PCR 
analysis, and maintained strong expression right through to passage 6 (Figure 3.3D). 
Thus, R-NSCs display the identity of NSCs. In fact, R-NSCs are found to express 
NSC markers even after 10 passages, albeit with a slight drop in their overall 
expression levels compared with earlier passages (data not shown). The RT-PCR 
results also showed relatively higher expression of GPC marker genes, NG2 and 
PDGFR, in neurospheres compared with R-NSCs (Figure 3.3D). This may indicate 
that either NSCs in the context of neurospheres express NG2 and PDGFR or that 
neurospheres contain a mixed population of cells, including a subpopulation of glial 
progenitors that highly express PDGFR and/or NG2. Therefore, these findings 
indicate that this adherent culture method provides a faster approach to generate 
NSCs from hESCs than the neurosphere culture method, acquiring plated NSCs 
within 2 weeks, and the generated NSCs could be propagated and maintained for a 
number of passages in monolayer culture with little signs of differentiation into GPCs. 


















Figure 3.3 Rosette NSCs derived from hESC express neuroectodermal markers. (A–
B) Generation of NSCs from hESC via neural rosette formation. (A) Neural tube-like 
rosette structures formed from adherent culture of H1-derived embryoid bodies on 
CELLstart-coated plates. (B) A monolayer of rosette NSCs (R-NSCs) after single-cell 
dissociation of isolated neural rosettes and replating on CELLstart-coated plates. (C) 
GPCs at passage 5 following in vitro differentiation of R-NSCs by exposure to GPC 
medium for 14 days. (D) RT-PCR analysis showed that R-NSC express neuroectodermal 
markers (PAX6, SOX2, SOX1, and Nestin) even at passage 6 (P6). R-NSC at P6 express 
comparatively lower levels of GPC markers NG2 and PDGFR than neurospheres (NS) 
cultured in NSC medium for 30 days. Actin served as loading control. The no-RT control, 
representing RT-PCR in the absence of reverse transcriptase, shows absence of genomic 
DNA contamination. Scale bar: 100 µm. 
5Figure 3.3 Rosette NSCs derived from hESC express neuroectodermal markers 
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3.2.3 Downregulation of early neuroectodermal genes and upregulation 
of GPC markers during differentiation from NSCs to GPCs 
Subsequent to deriving NSCs from hESCs, we proceeded to further differentiate the 
NSCs into GPCs using a simplified approach that was adapted from protocols used 
to generated O-2A progenitors or oligodendrocytes and involved treatment with 
PDGF-AA and bFGF (Kang et al., 2007; Neri et al., 2010; Rao et al., 2009). The 
combination of bFGF and PDGF reportedly acts synergistically to maintain the 
proliferative capacity while inhibiting oligodendrocytic and astrocytic terminal 
differentiation of progenitors, thus allowing glial progenitors to undergo continuous 
self-renewal (Bögler et al., 1990). NS-NSCs (NSCs from hESC-derived neurospheres 
that were dissociated and cultured on matrigel) when cultured in GPC medium 
containing bFGF and PDGF-AA for 14 days produced an isomorphous population of 
bipolar cells (Figure 3.1D), the typical morphology of GPCs cultured in vitro (Roy et 
al., 1999). Similarly, R-NSCs when treated with GPC medium for 14 days generated 
cells with an elongated bipolar morphology (Figure 3.3C). 
The glial progenitor-like cells derived from NS-NSCs, which are referred to as NS-
GPCs, were assessed for expression of GPC and neuroectodermal markers by RT-
PCR analysis at passage numbers 1, 3 and 5 (corresponding to 6, 10 and 15 days 
post-differentiation) (Figure 3.4A). The neuroectodermal markers, PAX6, SOX2 and 
SOX1 are downregulated during differentiation from NSC to GPC. PAX6 showed the 
fastest downregulation with its transcriptional expression being turned off by day 10. 
In contrast, a more modest downregulation of PAX6 was observed at the protein 
level with PAX6 protein still detectable at 14 days post-differentiation into GPCs 
(Figure 3.4B); instead, protein expression of SOX2 showed a more pronounced 
downregulation with barely detectable levels at 7 days post-differentiation (Figure 
3.4C). On the other hand, the expression of GPC markers, NG2 and PDGFR, and 
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Figure 3.5 GPCs derived from neurosphere NSCs express glial progenitor markers.  
Flow cytometric analysis of GPCs derived from neurosphere NSCs (NS-GPC) 14 days 
post-differentiation from NSCs showed that 87% of the cells were PDGFR+ and 99.6% 
were NG2+. 70.7% of the cells were positive for both NG2 and A2B5. Background levels, 
indicated by the dotted peak in the histogram and the quadrant divisions in the dot-plot, 
were set up using isotyped-matched control antibodies such that 99% of the total cell 
population was present to the left of region M1 of the histogram and in the lower left 
quadrant of the dot-plot. PE-conjugated anti-human PDGFR, PE-conjugated anti-human 
A2B5 and APC-conjugated anti-human NG2 antibodies were used. 
 
7Figure 3.5 GPCs derived from neurosphere NSCs express glial progenitor markers 
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Likewise, R-NSCs were differentiated into GPCs by treatment with GPC medium. 
Flow cytometric analysis of the glial progenitor-like cells derived from R-NSCs, which 
we refer to as R-GPCs, at 5 and 14 days post-differentiation into GPCs revealed that 
while the starting population of NSCs was a heterogeneous mix of progenitors with 
47% of the R-NSC population expressing NG2, out of which about 23% co-
expressed A2B5, the fraction of NG2+ cells increased during differentiation towards 
GPCs as seen at Days 5 and 14 (Figure 3.6). By Day 14 of treatment with GPC 
medium, nearly all R-GPCs (~98%) expressed NG2 and 40% expressed both NG2 
and A2B5. It may be worth noting that the fraction of A2B5-expressing cells remained 
between 30 to 40% during the differentiation process. It suggests that the subset of 
A2B5+ neural cells present within the initial population of R-NSCs gained expression 
of NG2 and PDGFR during the process of differentiation towards GPCs as opposed 
to the initial NG2+ subpopulation gaining expression of A2B5 upon GPC 
differentiation. However, it remains to be examined if the A2B5+ and A2B5- 
populations truly differentiate along mutually exclusive paths into glial cells and also if 
the proportion of A2B5+ cells will increase or be enriched after long-term culture in 
GPC medium beyond 14 days. Interestingly, only a small fraction of R-NSCs express 
PDGFR (8.5%) which grew to 54.4% by Day 14 (Figure 3.6, leftmost panel). This 
indicates that PDGFR expression is acquired later than NG2 or A2B5 expression 
along the path of glial differentiation. Morphological changes in the R-NSCs during 
differentiation towards GPCs were also noted by forward-scatter and side-scatter 
profiles (Figure 3.6, rightmost panel). Forward scatter in the flow cytometric 
analysis gives a representation of the size or volume of cells while side scatter 
relates to the intracellular density and complexity of cells (it is also indicative of 
cytoskeletal organization). During differentiation into GPCs, there was a general 
decrease in side scatter of the R-NSCs, while the forward-scatter profile remained 
relatively unchanged. This correlates with the observed morphologies of R-NSCs and 
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R-GPCs which showed some changes in cytoskeletal organization without a distinct 
change in cell size (Figure 3.3B, C). 
Along with the increase in GPC marker expression in R-GPCs there was a 
concomitant downregulation of SOX2 at the mRNA and protein levels as determined 
by RT-PCR and Western blot analyses (Figure 3.7A, B). In comparison with NS-
GPCs, R-GPCs contained a lower percentage (<40%) of NG2+ A2B5+ PDGFR+ 
cells after 14 days of exposure to GPC medium (Figures 3.5 and 3.6). 
Correspondingly, the extent of downregulation of neuroectoderm markers, such as 
SOX2, appeared greater in NS-GPCs than R-GPCs with R-GPCs maintaining strong 
expression of SOX2 mRNA at 6 days post GPC differentiation (Figure 3.7A) and 
bearing detectable levels of SOX2 protein at 14 days post-differentiation (Figure 
3.7B) whereas NS-GPCs displayed greatly reduced SOX2 protein expression even 
at Day 7 post-differentiation (Figure 3.4C). It is possible that the proportion of R-
GPCs expressing PDGFR, NG2 and A2B5 may increase with prolonged exposure 
to GPC medium, however this was not investigated here. 
Overall, these analyses of GPC marker and neuroectodermal gene expression by 
RT-PCR, Western blotting and flow cytometry reveal that NSCs derived from hESCs 
by neurosphere culture or neural rosette adherent culture can generate GPC-like 
cells upon exposure to bFGF and PDGF-AA, although there might be as of yet 
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3.2.4 In vitro glioma-tropic properties of genetically modified hESC-
derived NSCs and GPCs 
We proceeded on to examine the functional potential of hESC-derived NSCs and 
GPCs as cellular vehicles for targeted gene delivery to tumor cells by deriving NSCs 
and GPCs from genetically modified hESCs expressing eGFP and testing their 
glioma-tropic ability by an in vitro migration assay. These eGFP-expressing hESCs 
were generated previously in our lab by Ramachandra et al. (2011) via a two-step 
process involving the generation of a master H1 hESC line bearing heterospecific 
loxP sites in the adeno-associated virus integration site 1 (AAVS1) locus by 
homologous recombination, followed by Cre recombinase-mediated cassette 
exchange using a baculoviral system to introduce a floxed eGFP gene specifically 
into the AAVS1 locus. 
EGFP-hESCs were differentiated into NSCs via the formation of neurospheres and 
these were examined for the expression of neuroectodermal genes, SOX2, SOX1, 
and PAX6 to determine that they were indeed of neural lineage (Figure 3.8B). The 
eGFP-NSCs displayed an upregulation of SOX1 and PAX6 while retaining SOX2 
mRNA expression at levels comparable to wild-type hESC-derived NSCs. The eGFP-
NSCs derived from eGFP-hESCs that were cultured for 4 weeks as neurospheres 
also maintained eGFP expression (Figure 3.8A, B). Furthermore, eGFP-NSCs could 
give rise to glial cells expressing GFAP and neurons expressing β-III tubulin, thus 
demonstrating their multipotentiality (Figure 3.8C, D). EGFP expression was still 
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Figure 3.8 EGFP-NSCs derived from eGFP-hESC display characteristics of NSCs. 
(A) Free-floating eGFP-hESC-derived neurospheres after 4 weeks in NSC medium. (B) 
RT-PCR analysis showed that neurospheres derived from eGFP-hESCs (eGFP-NSCs) 
express neuroectodermal markers PAX6, SOX2 and SOX1 when compared with eGFP-
hESC and wild-type hESC-derived neurospheres. Actin served as loading control. -RT 
control, representing RT-PCR in the absence of reverse transcriptase, shows absence of 
genomic DNA contamination. (C–D) Differentiation of eGFP-NSCs into glial cells (C) and 
neurons (D) as shown by immunocytochemistry with antibodies against GFAP and β-III 
tubulin, respectively. (Data presented here is published as Figure 5 in Nucleic Acid 
Research, 2011, 39(16): e107. doi:10.1093/nar/gkr409) 




The eGFP-NSCs were further differentiated into GPCs. The increase in expression of 
GPC markers NG2 and A2B5 was noted by flow cytometric analysis (Figure 3.9). 
Prior to GPC differentiation, the starting eGFP-NSCs that were cultured on matrigel 
for 3 days after dissociation from eGFP-neurospheres were found to be a mixed 
population with 66.6% of the cells expressing NG2. The peak in the NG2-expression 
profile of the starting eGFP-NSCs was however relatively spread out, indicating that 
there was a mixture of cells with mild, strong or no expression of NG2. Notably, not 
all eGFP-NSCs expressed eGFP with ~80% eGFP+. We suspect the loss of eGFP 
was due to epigenetic silencing of the eGFP transgene in some cells. Furthermore, 
the presence of dead or nonviable cells carried over from the neurosphere 
dissociation process could possibly contribute to the fraction of eGFP-negative cells. 
Nevertheless, after 15 days of GPC differentiation 97% of the cells expressed eGFP, 
likely due to the expansion of the viable eGFP-expressing cells, and the sharp peak 
recorded indicates a relatively uniform eGFP expression among the cells. In addition, 
nearly all eGFP-GPCs at Day 15 post-differentiation expressed NG2 with ~90% 
expressing A2B5 as well. This strong expression of eGFP, NG2 and A2B5 was 
retained for an additional 9 days as observed at Day 24 post-differentiation. 
Altogether >90% of eGFP-GPCs expressed both NG2 and A2B5 at Day 24 of culture 







































Figure 3.9 EGFP-GPCs derived from eGFP-NSC express glial progenitor markers. 
Flow cytometric analysis of eGFP-NSCs at day 3 of culturing on matrigel in NSC medium 
after dissociation from neurospheres, and eGFP-GPCs derived from eGFP-NSCs at 15 
and 24 days post-differentiation in GPC medium. NG2 and A2B5 expression frequencies 
were assessed using APC-conjugated monoclonal antibodies against A2B5 and NG2. 
Background level, indicated by the dotted peak, was set up using isotyped-matched 
control antibodies such that 99% of the total cell population was present to the left of 
region M1. 
11Figure 3.9 EGFP-GPCs derived from eGFP-NSC express glial progenitor markers 
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We had previously generated hESCs expressing HSVtk suicide gene (TK-hESCs), 
derived NSCs from these TK-hESCs via neurosphere culture (TK-NSCs), 
demonstrated the in vitro tumor killing effect of TK-NSCs and examined their glioma 
migratory ability by an in vitro migration assay (reported in Figure 6 of Ramachandra 
et al., 2011). In the current study, the glioma-tropic potential of eGFP-GPCs was 
tested using a modified Boyden chamber assay (Figure 3.10A). Nearly all the cells 
(>90%) expressed eGFP and thus did not need to be labeled or stained for 
monitoring. EGFP-GPCs showed ~1.7 folds greater migration towards human glioma 
U87 cells than plain Opti-MEM medium alone (Figure 3.10B, C). The previous and 
current results suggest that our hESC-derived NSCs and GPCs are potentially 
functional for targeting of tumors, although their in vivo tumor migratory property still 









































Figure 3.10 EGFP-GPCs derived from eGFP-NSCs display tumor tropism. (A) An 
illustration of a Boyden chamber. (B) Migrated eGFP-GPCs on the bottom side of the 
insert membrane after 24-hr incubation in plate wells with unsupplemented Opti-MEM 
alone or with U87 human glioblastoma cells. Scale bar: 100 µm.  (C) Relative migration of 
eGFP-GPCs towards U87 glioma cells. Each group consisted of five independent repeats 
with five imaged fields being counted for each repeat. Data represent mean ± SD. (**: p-
value<0.01 by t-test when compared to migration towards Opti-MEM) 




3.3.1 hESC-derived NSCs 
The ability to generate, from hESCs and iPS cells, expandable NSC populations with 
the innate capacity to give rise to the three major neural cell types, holds promise of 
a viable option for large-scale therapeutic applications. Over the years, numerous 
protocols have been developed and described for the derivation of NSCs and neural 
progenies from ESCs. These protocols typically involved enrichment and 
maintenance of NSCs by neurosphere suspension culture or by adherent culture. In 
this study, we have successfully obtained multipotent NSCs that expressed 
neuroectodermal markers via a neurosphere culture approach and, separately, via an 
adherent culture approach involving formation and selection of neural rosettes. 
The neurosphere culture method has some advantages over the neural rosette 
adherent culture approach but also suffers from several limitations. The former 
presents a facile approach to derive NSCs without the need for complicated selection 
procedures, such as the selection of neural rosettes. Furthermore, the context within 
a neurosphere may function as a micro NSC niche, providing the necessary cell-cell 
and extracellular matrix-cell contacts for self-renewal and maintenance of the NSC 
population (Jensen and Parmar, 2006; Sirko et al., 2010) – neurospheres were found 
to contain NSC populations based on the strong expression of neuroectodermal 
markers and displayed neurogenic and gliogenic potential even up to 4 months in 
culture (Reubinoff et al., 2001). In contrast, NSC adherent cultures, which include 
those from replating of isolated neural rosettes as well as from plating of dissociated 
neurospheres, could be maintained for a very limited number of passages before 
losing expression of NSC markers. In general, we found that within 10 passages, our 
NSC adherent cultures were bereft of most neuroectoderm gene expression, 
although neurosphere NSCs when dissociated and cultured as a monolayer 
displayed a more rapid loss of NSC markers (data not included). We surmise that this 
74 
 
may be due to asymmetric division of NSCs that give rise to more proliferative transit-
amplifying neural progenitors. In the context of the adult brain, the asymmetric 
division of NSCs is important for the homeostasis of brain tissue to maintain a 
constant population of NSCs, but in NSC culture, asymmetric division will 
progressively ‘dilute out’ the stem cell population with each passage. NSC adherent 
cultures are also sensitive to variations in the seeding density of cells which affect the 
proliferative capacity and self-renewal of NSCs. We observed that low cell densities 
tend to reduce proliferative capacity and promote differentiation. 
Nevertheless, neurospheres, as Jensen and Parmar (2006) aptly put it, represent 
‘little black boxes’ that cannot be peered into, making it difficult to determine cell 
numbers or monitor the properties of cells within each neurosphere. In contrast, NSC 
adherent cultures allow monitoring of cell numbers and morphological changes 
during the culture period, and permit a more uniform transfection or viral transduction 
of cells than neurosphere cultures. Another limitation of neurospheres is that they are 
heterogeneous in nature with each neurosphere containing a mixture of cells at 
different stages of differentiation, including NSCs, neural progenitors and postmitotic 
glial or neuronal cells (Reynolds and Rietze, 2005; Suslov et al., 2002). This 
heterogeneity increases over the period of time in culture and there is currently no 
available method to convincingly determine the percentage of bona fide NSCs within 
each neurosphere. However, this issue of heterogeneity is not limited to neurosphere 
cultures. We noted heterogeneity in both our hESC-derived neurospheres and 
adherent NSC cultures based on the expression of GPC markers. There have been 
reports that under most culturing conditions, regardless as neurospheres or adherent 
monolayers, NSCs display increased gliogenic bias and a decline in neurogenic 
capacity after prolong culture (Elkabetz et al., 2008; Fricker et al., 1999; Itsykson et 
al., 2005; Jensen and Parmar, 2006). And although recent methods involving neural 
rosette formation were able to demonstrate improved neurogenic potential of NSCs 
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in long-term culture over previous methods, they are still not close to being able to 
maintain pure NSC populations and generate all types of neuronal and glial cells 
efficiently (Elkabetz et al., 2008; Wilson and Stice, 2006). Thus, the challenge 
remains to develop more robust and reproducible differentiation protocols to generate 
pure populations of NSCs, specific neural progenitors and committed cells; a 
challenge that is made difficult by the lack of understanding of the molecular 
pathways involved. This provides the rationale for the next chapter of this thesis, 
which is to gain insights into the molecular mechanism involved in NSC differentiation. 
With regard to the issue of heterogeneity in NSC cultures, a prevailing phenomenon 
in development is that the transition from pluripotency to multipotency and eventually 
to committed cells occurs as a continuum rather than in discrete stages. This makes 
it problematic to determine exactly when a cell becomes an NSC and when its stops 
being one. And though, through the use of mitogens and growth factors, we seek to 
synchronize the development of cells within an NSC culture, it is more likely that the 
cultured cells are at variable points along this developmental continuum. Hence, 
heterogeneity seems to be the nature of things and true homogeneity in cell culture is 
nothing but a concept. 
 
3.3.2 hESC-derived GPCs 
GPCs have been widely studied for their potential as cellular strategies to treat 
demyelinating diseases. While several studies have described the derivation of 
GPCs from hESCs or from human fetal NSCs and demonstrated their efficacy in 
generating oligodendroglial progeny and in ameliorating demyelinating disorders after 
transplantation into animal models, most of these derivation protocols required the 
use of many mitogens or involved long culturing periods (Kang et al., 2007; Keirstead 
et al., 2005; Neri et al., 2010; Nistor et al., 2005). In this study, we have reproducibly 
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derived expandable populations of GPCs expressing the relevant GPC markers from 
hESC-derived NSCs by a new and simple approach adapted from existing protocols. 
Although we have yet to demonstrate the capacity of our GPCs to generate 
oligodendrocytes and astrocytes, we have shown that simply by exposure to bFGF 
and PDGF-AA a high percentage of NG2-expressing (>95%) GPCs could be 
generated within 14 days. Furthermore, a large proportion of these NG2+ GPCs were 
positive for the ganglioside-specific antigen A2B5 (at least 70% for GPCs derived 
from NS-NSCs) and for PDGFR (>85% for GPCs derived from NS-NSCs). Hence, 
our findings were in line with studies in rodents demonstrating that the growth factor 
PDGF promotes growth of glial progenitors in vitro and in vivo (Assanah et al., 2009; 
Bögler et al., 1990). It has been that suggested by Neri et al. (2010) that the 
generation of large pools of GPCs from NSCs by exposure to mitogens occurs 
through a mechanism of selection more than a mechanism of induction. However, it 
remains to be examined whether PDGF-AA selectively expands the population of 
GPCs within the NSC culture or it induces the differentiation of multipotent NSCs into 
lineage-restricted GPCs. Nevertheless, our data suggests that NG2 expression is 
acquired early during the process of GPC differentiation, and may even be expressed 
by a subpopulation of bona fide NSCs, while PDGFR expression appears at later 
stages in the NG2-positive cells. 
Corresponding to the increase in GPC marker expression in NSCs exposed to 
PDGF-AA, we noted a concomitant decrease in expression of early neuroectodermal 
markers which likely signifies a change from NSC to a gliogenic state. Among the 
NSC markers examined, nestin was the only one still expressed in GPCs, and rightly 
so, as nestin is a generic progenitor and precursor marker that is reportedly 
expressed in GPCs (Messam et al., 2002; Neri et al., 2010). There were some 
observed differences between the NSCs derived via neurosphere culture (NS-NSCs) 
and those derived via neural rosette adherent culture (R-NSCs) during differentiation 
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towards GPCs. R-NSCs retained expression of neuroectodermal gene SOX2 for 
longer than NS-NSCs during the period of GPC differentiation and produced a 
smaller proportion of GPCs expressing A2B5 or PDGFR at Day 14 of GPC 
differentiation than NS-NSCs as the same time point. This suggests that NSC 
potency may vary according to the method of their derivation and/or culturing 
conditions in vitro. However, further investigation would be required to elucidate the 
underlying differences between NSCs derived via the two methods. 
In this study we also demonstrated the derivation of NSCs and GPCs from a 
genetically modified hESC line bearing the eGFP gene in the AAVS1 site, and further 
showed the glioma migratory potential of the eGFP-GPCs. Previous studies on cell-
based gene delivery to brain tumors mainly involved NSCs or mixture populations of 
NSCs and neural progenitors (Aboody et al., 2000; Aboody et al., 2006; Benedetti et 
al., 2000), and others may have examined the migratory potential of GPCs towards 
demyelinated lesions in engraftment experiments (Sim et al., 2011; Windrem et al., 
2002), but glioma-targeting function has heretofore not been demonstrated 
specifically for GPCs. Our findings thus present one of the first in vitro evidences of 
the glioma-tropic ability of GPCs. The expression of eGFP is also particularly useful 
for tracking the eGFP-GPCs and may be exploited for monitoring of the in vivo 
migratory ability of these cells. Furthermore, the master hESC line bearing loxP-
docking sites in the AAVS1 locus that was generated in our previous study presents 
the possibility to insert virtually any target gene into the genome and opens the 
opportunity to generate GPCs expressing therapeutic transgene for cancer therapy 
or to treat demyelinating disorders. Our previous study demonstrating the generation 
of NSCs stably expressing the HSVtk suicide gene offers proof of this concept 




3.3.3 Future work 
While our results demonstrated that we were able to derive NSC populations from 
hESCs whether via the neurosphere method or the neural rosette adherent culture 
approach, these NSC populations were far from ‘pure’. Furthermore, long-term 
preservation of the NSC state and large-scale expansion still pose challenges that 
need to be addressed when contemplating clinical applications of ESC-derived NSCs. 
Insights into the underlying molecular mechanisms controlling NSC proliferation and 
fate choice would allow advancements to be made in NSC derivation methods and 
would contribute towards efforts to establish a definitive NSC identity. For a start, it 
may be of interest to investigate if the fraction of NG2+ or A2B5+ cells in the hESC-
derived NSC population are NSCs with both neurogenic and gliogenic potential, fate-
restricted progenitors or even non-neural cells. Even for our hESC-derived GPCs, a 
complete understanding of the fate of these cells is still lacking. And even though 
they express the characteristic markers of GPCs, further studies are required to 
characterize these cells and determine their ability to give rise to differentiated glial 
progenies. 
In terms of the glioma migratory potential of the hESC-derived GPCs, the next step 
would be to characterize the specificity and efficiency of the glioma-targeting ability of 
these cells in animal models of glioma. This would furnish us with information on the 
in vivo tumor migratory capacity of these cells and their potential for use in cell-based 
cancer therapy. We suspect that one of the mechanisms by which GPCs show 
migratory preference towards U87 glioma cells is mediated by the chemokine 
receptor CXCR4, which is found to be expressed by both NSCs and GPCs (Banisadr 
et al., 2011; Ni et al., 2004; Patel et al., 2010; Yip et al., 2006). Several studies, 
which demonstrated the important role of CXCR4 in the chemo-attraction of NSCs to 
neoplastic lesions and in the migration of GPCs to sites of demyelination, lend 
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support to this hypothesis (Banisadr et al., 2011; Yip et al., 2006). In addition, U87 
cells reportedly secrete VEGF which is known to induce attraction of human NSCs to 
tumor sites as well as promote the migration of GPCs, and thus may be a 
contributing factor to the observed attraction of GPCs in our in vitro migration assay 
(Cheng et al., 1996; Hayakawa et al., 2011; Schmidt et al., 2005). Hence, it may be 
worthwhile to investigate the expression level and glioma-targeting role of CXCR4 in 
our hESC-derived GPCs and the pathways underlying VEGF-mediated attraction of 
GPCs. These studies may uncover avenues to manipulate and enhance the specific 




Chapter 4: Regulation of neuroectodermal genes by 
miRNA 
4.1 Introduction and aims 
The importance of miRNAs in regulating the self-renewal and differentiation of NSCs 
has been emphasized by studies demonstrating that a regulatory network of miRNAs 
and transcription factors governs self-renewal and the fate of murine NSCs (Cheng et 
al., 2009; Conaco et al., 2006; Qureshi et al., 2010; Zhao et al., 2009). Gaining a 
better understanding of how these negative regulators modulate NSC differentiation 
may prove useful for designing protocols to derive and maintain NSCs or differentiate 
them into specific types of neuronal and glial cells for subsequent application in 
regenerative medicine. Current methods fall short of being able to effectively 
generate the diverse repertoire of neuronal populations. On the other hand, the range 
of glial populations is relatively limited and there are established methods to 
distinguish and isolate glial progenitors from other neural progenitors, thus glial 
differentiation presents a feasible starting point to dissect the mechanisms of NSC 
differentiation. Hence, we sought to examine the role of miRNAs during the 
differentiation of NSCs along the gliogenic pathway. 
In the previous chapter we demonstrated methods of deriving NSCs and GPCs from 
hESCs and noted that a loss of expression of several neuroectodermal genes, in 
particular PAX6 and SOX2, accompanied the increase in GPC marker expression 
during the differentiation of NSCs into GPCs. Interestingly, studies in vertebrates 
have established Pax6 and Sox2 to be determinants of the neuroectodermal fate, 
with Pax6 as a crucial factor of neurogenesis and Sox2 as a key regulator of NSC 
self-renewal (Favaro et al., 2009; Kallur et al., 2008; Maekawa et al., 2005; Quinn et 
al., 2007; Ring et al., 2012; Zhang et al., 2010c; Zhao et al., 2004). This led us to 
search for miRNAs that may regulate the expression of these two proneural 
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transcription factors. We probed the changes in miRNA expression profiles of NSCs 
during GPC differentiation by miRNA microarray and PCR analyses, and identified 
miRNAs that may potentially regulate PAX6 or SOX2 using a bioinformatics 
approach. We then determined the regulatory effect of selected miRNAs on the 
expression of PAX6 or SOX2 via miRNA gain-of-function and loss-of-function studies.  
For miRNA gain-of-function studies, two approaches were utilized, namely miRNA 
mimics and miRNA precursor expression vectors. miRNA mimics are 
oligonucleotides that resemble miRNAs and bear the exact sequence of the specific 
mature miRNA of interest. They are often chemically enhanced to preferentially load 
the active miRNA strand into RISC and are introduced into target cells by means of 
transfection, thus their effectiveness is largely dependent on the transfection 
efficiencies of target cells. The induced effect is also transient as they may be 
degraded overtime or get diluted as the transfected cells divide. Nevertheless, they 
offer a simple approach to study the short-term gain-of-function effects of a specific 
miRNA. miRNA precursor expression vectors on the other hand may be transfected 
as plasmids or incorporated into viral vectors for transduction. As such, depending on 
the vector used, they can offer transient overexpression through plasmid 
transfection or non-integrating viral transduction, or long-term overexpression 
through the use of integrating viruses. One caveat is that this approach involves 
the overexpression of pre-miRNAs that generate both the active miRNA strand 
and the passenger miRNA* strand, which could possibly result in confounding 
effects. 
For miRNA loss-of-function experiments, we utilized anti-miRNA oligonucleotides 
and miRNA decoys (or sponges). Anti-miRNA oligonucleotides are antisense 
oligonucleotides that bind with full complementarity to the sequence of the 
miRNA of interest. They are often chemically modified to enhance the 
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hybridization stability with the specific mature miRNA, thus mediating an effective 
miRNA-specific loss of function. Similar to miRNA mimics, anti-miRNA 
oligonucleotides are delivered into cells by transfection and mediate a transient 
miRNA loss-of-function as they are eventually degraded or diluted. Nonetheless, 
they offer a facile and convenient method to probe the function of a specific 
miRNA. In contrast, the miRNA decoy approach involves the transcription of an 
mRNA transcript containing several tandem repeats of a miRNA-specific target 
site. Overexpression of miRNA decoys thus draws the miRNA of interest away 
from its native mRNA targets and inhibits its regulatory function. Furthermore, 
depending on the vector used, the inhibition can be transient or long-term. In this 
study, we utilize baculoviral vectors for the transient and stable expression of 
miRNA decoys as well as for overexpression of pre-miRNA. Several features of 
baculoviruses make them advantageous for gene delivery to mammalian cells. This 
family of insect viruses is able to transduce a wide variety of mammalian cells without 
significant toxicity and does not replicate in mammalian cells (Kost et al., 2005). Due 
to their non-pathogenicity in humans and mammalian hosts, baculoviruses can be 
prepared and handled in biosafety level 1 facilities (Hu, 2006). Furthermore, their 
large cloning capacity, which allows incorporation of an insert size of at least 38 kb, 
and their ease of production using insect cell cultures makes baculoviral vectors a 
useful tool for gene expression studies (Cheshenko et al., 2001). 
 
4.2 Results 
4.2.1 miR-22, -21, -221 and -145 are upregulated in GPCs compared to 
NSCs and are predicted to target PAX6 mRNA 
In Chapter 3, we observed a more drastic loss of PAX6 and SOX2 expression in 
hESC-derived neurosphere NSCs than in rosette NSCs during differentiation into 
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13Figure 4.1 Pax6 is downregulated and NG2 is upregulated 5 days post-differentiation
towards GPC 
GPCs. Even at day 5 of exposure to GPC medium, ~72% of NS-GPCs were positive 
for NG2 expression, compared with 16.5% of the starting cells that were dissociated 
from hESC-derived neurospheres expressing NG2 prior to culture in GPC medium 
(Figure 4.1A). Correspondingly, PAX6 mRNA expression was downregulated in 
these 5-day GPC medium-treated cells (Figure 4.1B). Hence, we used Day 5 GPC 











Figure 4.1 Pax6 is downregulated and NG2 is upregulated 5 days post-
differentiation towards GPC. (A) Flow cytometric analysis showed that 71.8% of the 
hESC-derived neurosphere NSCs were NG2+ after culturing on matrigel in GPC medium 
for 5 days (NS-GPC day 5) compared to 16.5% of them being NG2+ after dissociation 
from neurospheres (NS) prior to culture in GPC medium. The background level indicated 
by the dotted peaks in the histograms was set up using isotyped-matched control 
antibodies such that 99% of the total cell population was present to the left of region M1. 
Percentages of positive cells are indicated. (B) RT-PCR analysis showed that PAX6 
expression is down regulated at 5 days post-differentiation from NSC to GPC. Actin 
served as loading control. The -RT control, representing RT-PCR in the absence of 




To determine if there are miRNAs involved in the downregulation of Pax6 during 
differentiation from NSC to GPC, we performed a two-color miRNA microarray 
analysis to identify the miRNAs that are upregulated during the differentiation 
process. We compared miRNA expression in NS-NSCs after 5 days exposure to 
GPC medium (labeled: GPC) with pre-differentiated NS-NSCs (labeled: NS) using 
the NCode Human miRNA Microarray V3 platform (Invitrogen) containing about 1112 
human miRNA probes. After collating the normalized data from three separate sets of 
microarray experiments, 19 known miRNAs were found to be elevated by more than 
2 folds in GPC over NSC. The miRNAs that were upregulated in the GPCs by 2 or 
more folds are listed in Table 4.1 along with their relative expression data. 
  
4Table 4.1 miRNAs identified by miRNA microarray analysis with increased 
expression during differentiation towards GPC 
Table 4.1 miRNAs identified by miRNA microarray analysis with increased 
expression during differentiation towards GPC.+ 




















+miRNA expression in 5-day post-differentiated GPCs was compared to that in NSCs by 
miRNA microarray. Ratios shown are the mean of three separate experiments (only 
miRNAs that are detected to have >2 fold increased expression in GPCs compared to 





5Table 4.2 RNA22 analysis of predicted target sites in PAX6 transcript for miRNAs 
identified by microarray analysis 
Table 4.2 RNA22 analysis of predicted target sites in PAX6 transcript for miRNAs 
identified by microarray analysis. The number of predicted sites in the coding sequence, 
3’ or 5’ UTRs of PAX6 transcript for each miRNA is indicated. 
miRNA ID 
# of predictions with fold energy < -20Kcal/mol 
5’ UTR CDS 3’ UTR Total 
hsa-miR-27a 2 - 4 6 
hsa-miR-100 - - 1 1 
hsa-miR-23a - 1 - 1 
hsa-miR-145 - 1 3 4 
hsa-let-7f - - 1 1 
hsa-miR-34a - - 10 10 
hsa-let-7a 2 1 - 3 
hsa-miR-22 - - 6 6 
hsa-miR-221 - 1 3 4 
hsa-let-7g 2 1 4 7 
hsa-miR-15a 1 - 3 4 
hsa-miR-23b 1 1 - 2 
hsa-miR-25 - - 1 1 
hsa-miR-21 1 1 1 3 
hsa-miR-24 - - 2 2 
hsa-miR-19a - - 2 2 
hsa-miR-132 - - 4 4 
 
The 19 miRNAs identified by the microarray analysis were then computationally 
analyzed for target sites in the PAX6 transcript using the miRNA target prediction 
algorithm RNA22. Unlike majority of miRNA target prediction algorithms which utilize 
3’ UTR cross-species conservation as the major component for prediction, RNA22 
employs a pattern-based approach for the identification of miRNA binding sites in the 
sequence of interest (Miranda et al., 2006). Hence, RNA22 generated predictions 
that covered sites which are not conserved and are not limited to the 3’ UTR. In 
addition, RNA22 permits target site prediction on the basis of ‘seedless’ match. The 
RNA22 analysis revealed that almost all the 19 miRNAs, with the exception of miR-
335 and miR-99b, had at least one predicted target site within the PAX6 transcript 
with high negative energy binding of less than -20 kCal/mol (Table 4.2). Though the 
human PAX6 gene has three known transcript variants produced by alternative 
splicing, with variants 1 and 3 encoding the PAX6a isoform and variant 2 encoding 
the PAX6b isoform, the predicted sequence alignment with the queried miRNAs was 




The expression levels of these 17 miRNAs, which are predicted to target PAX6, were 
subsequently verified by real-time qRT-PCR. The results revealed that only miR-21, -
22, -145 and -221 were upregulated by more than 2-fold in NS-GPCs after 5 days of 
treatment with GPC medium (Figure 4.2). Notably, only miR-145 expression showed 
an increasing trend along NSC to GPC differentiation from day 5 to 7. The 
discrepancy in miRNA expression profiles between the microarray and qRT-PCR 
analyses could be partly due to the low of sensitivity of the microarray technique and 
an overestimation of the signal intensity on the microarray. Nevertheless, our results 
suggest that the four miRNAs, miR-21, -22, -145 and -221, which are upregulated in 
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4.2.2 PAX6 is a prospective target of miR-22 and miR-221 
There has hitherto been no reports implicating any of the four miRNAs, miR-21, -22, -
145 and -221, in neurogenesis or gliogenesis, thus we proceeded on to examine their 
interaction with PAX6 gene. The predicted heteroduplexes with the two lowest fold 
energies for each of these four miRNAs are shown in Figure 4.3B. Notably, some of 
the predicted heteroduplexes formed between each of the four miRNAs and PAX6 
transcript contained one or more G:U wobble pairings or imperfect complementarity 
in the miRNA seed region. Nevertheless, previous studies have shown that miRNA 
binding with the occurrence of multiple G:U pairings or imperfect complementarity in 
the seed region can still be functional and mediate repression of the target gene 
(Brodersen and Voinnet, 2009; Friedman et al., 2009; Miranda et al., 2006). On the 
whole, the prediction of multiple target sites for the four miRNAs in PAX6 3’ UTR 
suggests the possibility of multiplicity and cooperativity of regulatory action by several 
miRNAs at multiple binding sites. 
Subsequently, we sought to validate the specificity of the predicted targeting by each 
of the four miRNAs via luciferase reporter assays. Majority of the predicted PAX6 
target sites of these four miRNAs fall in the 3’ UTR of the PAX6 transcript (Table 4.2). 
However, the large size of the PAX6 3’ UTR (~5000 bp) might impede cloning and 
transfection efficiencies. Hence, for the luciferase assays we constructed luciferase 
reporter vectors (pMIR-pax6-1.9k, pMIR-pax6-3.4k and pMIR-pax6-4k) with each of 
the three subfragments of PAX6 3’ UTR (pax6-1.9k, pax6-3.4k and pax6-4k) cloned 
downstream of the luciferase reporter gene (Figure 4.3A). The pax6-1.9k fragment 
contains one predicted target site for miR-21 and three for miR-145, while pax6-3.4k 











Human Pax6, transcript variant 1, mRNA (~6947 bp) 
CDS (534–1802) 3’UTR (1803–6947)
A 
 position 3469–3490  position 4637–4658 
PAX6 3’UTR  5’→3' 
 
hsa-miR-22  3’→5' 
---GGCCTTCAGTCATTGGCAGCTT 
   |  |||||   |:||||||||| 
UGUCAAGAAGU---UGACCGUCGAA 
GGCAGGCTCTGTG--TGGTAGCAG 
  :|||  |||     |||:||| 
-UGUCA-AGAAGUUGACCGUCGAA 
 fold energy = -34.4 kcal/mol fold energy = -25.8 kcal/mol
 
 position 4632–4654 position 5630–5652 
PAX6 3’UTR  5’→3' 
 
hsa-miR-221  3’→5' 
--AGCATGGCAGGCTCTGTGTGGTA 
  |:| ::||||:    :|||:|: 
CUUUGGGUCGUCUGU--UACAUCGA 
AA-----AGTAGATATTGTATGGTGGCT  
       ||:|||:|       ||:||| 
CUUUGGGUCGUCUGUUA-----CAUCGA 
 fold energy = -28.9 kcal/mol fold energy = -27.7 kcal/mol
 
 position 608–629 position 4171–4192 
PAX6 3’UTR  
5’→3' 
CCGGCAGAAGATTGTAGAGCTA 
 |::||  || :||  :||||| 
AGUUGUAGUCAGACUAUUCGAU 
AGCCTACATTCC-CTGA-GGGCTG 
   | ||||:   |||| ::|||: 
A--GUUGUAGUCAGACUAUUCGAU 
 position 3132–3154  position 5147–5169 
PAX6 3’UTR  
5’→3' 
--GGA---CTGGCATTTTCAATCTGGGC 
  |||   ||||          ||||:| 
UCCCUAAGGACCCUUUU-----GACCUG 
GCTTATTTCTTTTTACTCTGGGC   
    |||:||       ||||:| 
UCCCUAAGGACCCUUUUGACCUG 
Figure 4.3 Predicted binding sites for miR-22, miR-221, miR-21 and miR-145 in PAX6 
3’ UTR. (A) Schematic representation of PAX6 transcript and PAX6 3’ UTR subfragments, 
pax6-1.9k (blue), -3.4k (purple) and -4k (green) that were tested experimentally. Pax6-
1.9k contains one and three predicted target site(s) for miR-21 and -145, respectively. 
Pax6-3.4k contains five miR-22 predicted target sites while pax6-4k contains three miR-
221 predicted target sites. (B) Predicted miRNA:mRNA heteroduplexes between each of 
the four miRNAs and PAX6 3’UTR. Predicted heteroduplexes with the lowest two fold 





The luciferase reporter assays were performed in HeLa cells as we had found that 
they had significantly lower endogenous levels of miR-21, -22, -221 and -145 than 
hESC-derived GPCs at Day 7 post-differentiation from NSCs (Appendix Figure A1), 
and thus would avoid interference from endogenous miRNAs. We transfected HeLa 
cells with the luciferase reporter constructs together with either the corresponding 
miRNA mimic or the miRNA negative control (mIRIDIAN miRNA negative control 2, 
Dharmacon). A β-galactosidase control plasmid was also co-transfected to serve as 
a control for transfection efficiency. The functional binding of a miRNA to the target 
sites would result in a measurable reduction in luciferase activity. The luciferase 
activities of pMIR-pax6-3.4k and pMIR-pax6-4k were suppressed with the addition of 
miR-22 and miR-221 mimics, respectively, compared with the negative control 
(Figure 4.4B, C). miR-22 reduced luciferase expression by about 40% for pMIR-
pax6-3.4k compared to the negative control, while miR-221 suppressed luciferase 
expression of pMIR-pax6-4k by about 50% below negative control levels. In contrast, 
miR-145 and miR-21 did not significantly suppress luciferase activity of pMIR-pax6-
1.9k (Figure 4.4A). The predicted sites for miR-145 and miR-21 appear to be non-
functional under these experimental conditions. In a similar experiment, where HeLa 
cells were cotransfected with pMIR-pax6-3.4k and miR-22 mimic or miRNA negative 
control, along with miR-22 hairpin inhibitor or miRNA inhibitor negative control, miR-
22 suppression of the luciferase activity of pMIR-pax6-3.4k was shown to be inhibited 
by the miR-22 hairpin inhibitor (Figure 4.4D). Therefore, these results demonstrate 
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Figure 4.4 miR-22 and -221 possibly downregulate PAX6 by specific targeting of 
PAX6 3’ UTR. (A–C) Luciferase reporter assay showed pMIR-pax6-3.4k and pMIR-pax6-
4k luciferase reporter activities were reduced in the presence of miR-22 and miR-221 
mimics respectively, while miR-21 and miR-145 mimics had no significant effect on the 
activity of pMIR-pax6-1.9k. Luciferase reporter constructs pMIR with pax6-1.9k, -3.4k or -
4k fragments were co-transfected with specific miRNA mimics or miRNA mimic negative 
control into HeLa cells. (D) Specific targeting of PAX6 3’ UTR by miR-22. Luciferase 
reporter construct pMIR-pax6-3.4k was co-transfected with different combinations of miR-
22 or miRNA negative control mimics, and anti-miR-22 or miRNA inhibitor negative control 
into HeLa cells. Luciferase assay was measured and normalized to β-galactosidase 
expression after 48-hr incubation, and expressed as relative light unit (RLU) per β-gal unit 
of activity. Data represent means ± SD of four independent transfections. (*: p-value<0.05 
by t-test when compared to relevant controls) 
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To further ascertain the regulatory effect of miR-22 and miR-221 on PAX6 expression, 
ReNcell NSCs, which express PAX6, were transfected with miR-22 or miR-221 
mimics and PAX6 protein levels were examined. Unfortunately, western blot analysis 
showed no significant change in PAX6 protein expression when compared with the 
controls that were transfected with either mimic negative control 1 or 2 (Figure 4.5). 
A transfection control that was carried out by transfecting a fluorescent-labeled 
control miRNA mimic revealed that most of the control mimics aggregated at the cell 
membranes as opposed to being uniformly distributed in the cytoplasm within the 
cells (Figure 4.6). From this it seems that ReNcell NSCs are not permissive to 
transfection and we suspect that the function of the membrane-aggregated mimics 
may be impaired, thus resulting in the lack of change in PAX6 protein expression in 
the transfected cells. Hence, without a tried and tested approach to simply and 
effectively induce miR-22 or miR-221 expression in NSCs we did not pursue this line 
of investigation further, and miR-22 and miR-221 still remain as prospective 
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Figure 4.5 Effect of miR-22 and -221 on PAX6 and SOX2 expression in ReNcell 
NSCs. Western blot analysis of PAX6 and SOX2 in ReNcell NSCs 72 hours after 
transfection with miR-22, miR-221, or negative control mimics. Densitometry was 
performed using ImageJ software and protein amounts are normalized to β-actin loading 
control and presented relative to miRNA mimic negative control 2. 
Merged 
Fluorescence Phase contrast
Figure 4.6 Transfection of ReNcell NSCs with miRNA mimic transfection control. 
ReNcell NSCs were transfected with control miRNA mimics labeled with Dy547 
fluorescent dye. Most of the fluorescent labeled miRNA mimics appeared aggregated at 
the cell membrane (indicated by yellow arrows) rather than filling the cytoplasm and 
nucleus of transfected ReNcell NSCs. 
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19Figure 4.7 Predicted binding site for miR-145 in SOX2 3’ UTR 
4.2.3 miR-145 is predicted to target SOX2 
Similar to PAX6, SOX2 expression was also downregulated during the differentiation 
from NSCs to GPCs (Figure 3.4 and 3.7). This led us to question whether the four 
miRNAs, miR-21, -22, -145 and -221, that were identified to be upregulated in GPCs 
had a role in repressing SOX2 expression. We performed target prediction analysis 
to identify potential target sites of these miRNAs in the SOX2 transcript. The in silico 
anaylsis revealed several sites in SOX2 mRNA with high negative energy binding for 





Fortuitously, miR-145 was recently reported to directly target SOX2 and repress its 
expression in hESCs (Xu et al., 2009). Xu and colleagues demonstrated that miR-
145 represses pluripotency and regulates differentiation of hESCs by acting on SOX2, 
OCT4 and KLF4. They confirmed that miR-145 repressed SOX2 gene expression by 
targeting a conserved site in the 3’ UTR of SOX2 mRNA, which was also identified in 
our target prediction analysis (Figure 4.7), via a luciferase reporter assay (Appendix 
Figure A2). They further demonstrated that ectopic expression of miR-145 in hESCs 
repressed SOX2 expression (Appendix Figure A3). Hence, we set out to determine 
if miR-145 is likewise a negative regulator of SOX2 in NSCs. 
  
6Table 4.3 Predicted target sites in SOX2 transcript for miR-21, -22, -221 and -145 
Table 4.3 Predicted target sites in SOX2 transcript for miR-21, -22, -221 and -145. The 
number of predicted sites in the coding sequence, 3’ or 5’ UTRs of SOX2 transcript for 
each miRNA is indicated. 
miRNA ID 
# of predictions with fold energy < -20Kcal/mol 
5’ UTR CDS 3’ UTR Total 
hsa-miR-21 1 1 1 3 
hsa-miR-22 1 2 1 4 
hsa-miR-221 1 1 - 2 
hsa-miR-145 - - 1 1 
 
            position 1390–1410 
SOX2 3’UTR  5’→3'
hsa-miR-145  3’→5'
AGGG---CC--GGACAGCGAACUGGAG 
||||   ||  |||    :||||||| 
UCCCUAAGGACCCU----UUUGACCUG 
  fold energy = -23.8 kcal/mol 
 
Figure 4.7 Predicted binding site for miR-145 in SOX2 3’ UTR. Predicted heteroduplex 
between miR-145 and SOX2 3’ UTR is shown with the seed region underlined. 
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4.2.4 SOX2 is downregulated by miR-145 in NSCs 
Towards the aim of elucidating the regulatory effect of miR-145 on SOX2 expression 
in hESC-derived NSCs, we examined the expression of SOX2 in hESC-derived NS-
NSCs and R-NSCs so as to determine which of them would best serve this purpose. 
Immunostaining for SOX2 revealed that hESC-derived NSCs were a heterogeneous 
mixture of cells with strong to no expression of SOX2 (Figure 4.8). Even ReNcell 
NSCs showed some heterogeneity in terms of the level of SOX2 expression in the 
cells. Nonetheless, a greater proportion of the cells expressed SOX2 protein in 
hESC-derived R-NSCs as compared with NS-NSCs, thus we chose to use R-NSCs 
for subsequent experiments to examine the effect of miR-145 on SOX2. ReNcell 
NSCs were used as a study control to validate that the results observed could be 
extended to human NSCs in general. A reason for the higher proportion of SOX2-
expressing cells in R-NSCs could be due to the stricter selection and expansion 
criteria involved in the method of deriving R-NSCs from hESCs as compared with 
neurosphere culture method. 
Similar to the observed trend of increasing miR-145 levels in NS-NSCs during 
differentiation towards GPCs (Figure 4.2), R-NSCs exhibited an increase in miR-145 
expression along the differentiation from NSC to GPC, albeit milder than in NS-NSCs 
(Figure 4.9). R-GPCs at Days 6 and 7 post-differentiation showed a 1.9-fold and 5.7-
fold greater expression of miR-145 over R-NSCs, respectively. Thus, the 
upregulation of miR-145 during the differentiation of NSCs to GPCs is a phenomenon 
independent of the method of NSC derivation and likely has physiological 
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Our previous attempt to study the regulatory function of miRNAs on PAX6 expression 
was hindered by the poor transfectability of NSCs. Here, transfection of ReNcell 
NSCs with miR-145 mimics (as well as other miRNA mimics) yielded variable or 
insignificant changes in SOX2 protein expression (Appendix Figure A4). Hence, we 
proceeded to test the efficiency of transfecting ReNcell NSCs with plasmid vectors 
that express a reporter gene, either eGFP or mCherry, and pre-miR-145 or miR-145 
inhibitory decoy (Figure 4.10A). Visually, relatively few transfected cells exhibited 
strong expression of the reporter gene (Figure 4.10B). Flow cytometric analysis 
revealed that less than 20% of the transfected ReNcell NSCs expressed eGFP or 
mCherry reporter (Figure 4.10C). The presence of cells with strong reporter gene 
expression indicates that the plasmid constructs were functional and the lack of 
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To circumvent the issue of poor transfectability in NSCs, we cloned the pre-miR-145 
and miR-145 inhibitor expression cassettes shown in Figure 4.10A into baculoviral 
vectors which have been shown to efficiently transduce a number of cell types 
including hESCs and hESC-derived neurons (Zeng et al., 2009; Zeng et al., 2007). 
We examined the transduction efficiency of the baculoviral vectors in ReNcell NSCs 
and found that, visually, more cells transduced with baculovirus expressed the 
reporter gene than cells transfected with the corresponding plasmid vector (Figure 
4.11A and 4.10B). Flow cytometric analysis 48 hours after baculovirus transduction 
showed that the percentage of transduced ReNcell NSCs expressing eGFP or 
mCherry was about double that of transfected ReNcell NSCs (Figure 4.11B and 
4.10C). Additionally, at least 66% of hESC-derived R-NSCs following baculovirus 
transduction expressed eGFP or mCherry. EGFP expression is equivalent to 
expression of pre-miR-145 or a scrambled sequence with no homology to the human 
genome, while mCherry expression is akin to expression of anti-miR-145 decoys or 
scrambled decoys that are not complementary to any known human miRNA. 
Therefore, baculoviral vectors appear to be more feasible than plasmid vectors to 
generate an upregulation of miR-145 expression or to inhibit miR-145 function by 
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Figure 4.11 Baculovirus transduction efficiency of ReNcell NSCs and R-NSCs. (A) 
Image of ReNcell NSCs 48 hours after transduction with baculoviral vector expressing 
miRNA inhibitor control with mCherry reporter gene at an MOI of 50. (B) Flow cytometric 
analysis of ReNcell NSCs and R-NSCs 48 hours after transduction with baculoviral 
vectors expressing miR-145/scrambled control with eGFP reporter gene (BV-miR-scr or 
BV-miR-145), or anti-miR-145/inhibitor control with mCherry reporter gene (BV-Inh Ctrl or 
BV-anti-miR-145). The background level indicated by the dotted peaks was set up using 
untransfected ReNcell NSCs or R-NSCs such that 99% of the total cell population was 
present to the left of gated region. Percentages of fluorescing cells are indicated. 
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We transduced ReNcell NSCs and hESC-derived R-NSCs with baculovirus 
expressing pre-miR-145 (BV-miR-145) or anti-miR-145 decoys (BV-anti-miR-145) at 
an MOI of 50 to effectuate an upregulation or loss-of-function of miR-145, 
respectively, and studied the effect on the mRNA and protein levels of SOX2. To rule 
out the effects of baculovirus transduction, we transduced cells with the 
corresponding baculoviral vectors expressing scrambled miRNA (BV-miR-scr) or 
scrambled decoys (BV-Inh Ctrl) in parallel as a control. Two days after baculovirus 
transduction, miR-145 levels were upregulated in ReNcell NSCs and R-NSCs 
transduced with BV-miR-145 by 9.3 folds and 2.6 folds respectively over the 
corresponding controls (Figure 4.12A). The degree of upregulation of miR-145 due 
to transduction with BV-miR-145 appears to be comparable to the endogenous 
increase in miR-145 levels in R-NSCs during GPC differentiation (Figure 4.9). 
Furthermore, the increase in miR-145 levels was able to reduce the levels of SOX2 
protein in both ReNcell NSCs and R-NSCs as shown by Western blot analysis 
(Figure 4.12E). The relative fold change in SOX2 protein levels shown in Figure 
4.12E were found to be statistically significant. Quantitative real-time RT-PCR 
showed that there was no change to SOX2 expression at the mRNA level in both 
ReNcell NSCs and R-NSCs (Figure 4.12C). These results suggest that miR-145 
likely represses the translation of SOX2 without inducing mRNA destabilization or 
degradation in NSCs. In a similar but reverse manner, inhibition of endogenous miR-
145 by transduction with BV-anti-miR-145 resulted in upregulation of SOX2 protein 
levels in both ReNcell NSCs and R-NSCs without significant changes to SOX2 
mRNA levels as revealed by Western blot analysis and qRT-PCR, respectively 
(Figure 4.12D, F). Interestingly, miR-145 levels in R-NSCs transduced BV-anti-miR-
145 were reduced but were not significantly altered in ReNcell NSCs (Figure 4.12B), 
which could be due to ReNcell NSCs having lower levels of endogenous miR-145 
than R-NSCs.  
102 
 





















































































































Figure 4.12 Effect of miR-145 on endogenous SOX2 in ReNcell NSCs and R-NSCs. 
(A–B) Relative miR-145 levels in ReNcell NSCs and hESC-derived rosette NSCs (R-
NSCs) 48 hours after transduction with baculovirus expressing miR-145 (BV-miR-145) (A) 
or anti-miR-145 (BV-anti-miR-145) (B) at an MOI of 50 were quantified by qRT-PCR. 
Values were normalized to 5S rRNA and presented relative to miR-145 levels in cells 
transduced with baculorvirus expressing miRNA scrambled control (BV-miR-scr) (A) or 
inhibitor control (BV-Inh Ctrl) (B). (C–D) Relative SOX2 mRNA expression in ReNcell 
NSCs and R-NSCs 48 hours after transduction with BV-miR-145 (C) or BV-anti-miR-145 
(D) at an MOI of 50 were quantified by qRT-PCR. Values are normalized to GAPDH and 
expressed relative to SOX2 mRNA levels in cells transduced with BV-miR-scr (C) or BV-
Inh Ctrl (D). Data represents mean + SD of triplicates. (*: p-value<0.05 and **:p-
value<0.01 by t-test when compared to relevant controls.) (E–F) Western blot analysis of 
SOX2 in ReNcell NSCs and R-NSCs 48 hours after transduction with BV-miR-145 (E) or 
BV-anti-miR-145 (F) at an MOI of 50. Densitometry was performed using ImageJ 
software. Protein amounts are normalized to β-actin loading control and presented relative 
to SOX2 protein levels in cells transduced with BV-miR-scr (E) or BV-Inh Ctrl (F). Data 
presented are representative of three independent experiments.  
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To further verify that miR-145 was solely responsible for the observed 
downregulation of SOX2 protein levels, we transduced R-NSCs with both BV-miR-
145 and BV-anti-miR-145 at an MOI of 25 for each. The expression of anti-miR-145 
decoys was able to attenuate the upregulation of miR-145 levels in R-NSCs 
transduced with both BV-miR-145 and BV-anti-miR-145 (Figure 4.13A). 
Correspondingly, the downregulation of SOX2 protein expression caused by ectopic 
miR-145 expression was abrogated in these R-NSCs (Figure 4.13C). At the mRNA 
level, there was again no significant change in SOX2 expression (Figure 4.13B). 
Overall, these findings indicate that miR-145 mediates translational repression of 
SOX2 and suggests that endogenous miR-145 continuously fine-tunes the level of 
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Figure 4.13 miR-145 inhibitor attenuates the downregulation of endogenous SOX2 
induced by ectopic expression of miR-145. (A) qRT-PCR analysis of relative miR-145 
levels in R-NSCs 48 hours after transduction with a dual combination of baculoviral 
vectors expressing either miR-145 or scrambled control and either anti-miR-145 or 
inhibitor control at an MOI of 25 for each vector. Values were normalized to 5S rRNA and 
presented relative to miR-145 levels in R-NSCs transduced with baculorviral vectors 
expressing miRNA scrambled and inhibitor controls. (B) Corresponding relative SOX2 
mRNA expression in R-NSCs 48 hours after transduction with the vector combinations in 
(A) were quantified by qRT-PCR. Values are normalized to GAPDH and expressed 
relative to SOX2 mRNA levels in R-NSCs transduced with baculorviral vectors expressing 
miRNA scrambled and inhibitor controls. Data represents mean + SD of triplicates. (**:p-
value<0.01 by t-test when compared to relevant controls.) (C) Western blot analysis of 
SOX2 in R-NSCs 48 hours after transduction with the vector combinations in (A). 
Densitometry was performed using ImageJ software. Protein amounts are normalized to 
β-actin loading control and presented relative to SOX2 protein levels in R-NSCs 
transduced with both BV-miR-scr and BV-Inh Ctrl. Data presented are representative of 




miRNAs have been implicated as key regulators in a broad range of developmental 
pathways. Especially with numerous studies demonstrating the importance of 
miRNAs in self-renewal and differentiation of NSCs in mice, it was only logical to 
believe that miRNAs may regulate the fate decision processes of NSCs in man too. 
Here, for the first time, the miRNA expression profiles of hESC-derived NSCs and 
GPCs were examined via methods such as a miRNA microarray, and, as anticipated, 
we were able to identify several miRNAs that were upregulated in hESC-derived 
NSCs during the process of differentiation into GPCs, namely miR-21, -22, -221 and -
145. We further demonstrated that miR-22 and miR-221 could target the 3’ UTR of 
PAX6. Although downstream gain/loss-of-function experiments were hampered by 
the low efficiency of transfection in NSCs and we were unable to validate this 
targeting of PAX6 in NSCs at the time of writing this thesis, our findings suggest a 
link between miRNAs and core transcription factors regulating NSC fate specification. 
In addition, our observations of PAX6 downregulation during GPC differentiation 
were consistent with previous findings that PAX6 is a potent neurogenic factor that 
drives NSCs towards neuron formation at the expense of astrocytes (Heins et al., 
2002; Kallur et al., 2008) and that Pax6 ablation in Pax6–/– mice resulted in premature 
specification of oligodendrocytes and astrocytes in spinal cord development 
(Sugimori et al., 2007). 
SOX2 is another key transcription factor that was observed to be downregulated 
during GPC differentiation in NSCs. This was in agreement with the role of SOX2 as 
an essential factor for self-renewal of NSCs, and with studies in mice demonstrating 
Sox2 to be an antagonist of neuronal and glial differentiation in NSCs, although the 
mechanisms by which it does so are still not clearly understood (Cavallaro et al., 
2008; Ferri et al., 2004; Graham et al., 2003; Ring et al., 2012). The recent study by 
Xu et al. (2009), demonstrated that miR-145 represses SOX2 expression in hESCs 
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and regulates the shift from pluripotency to differentiation. This thesis extends upon 
these findings by showing here that upregulation of miR-145 was able to suppress 
SOX2 expression in human NSCs. Our data suggests that miR-145 contributed to 
the downregulation of SOX2 protein levels during GPC differentiation and that a 
small increase (~2 to 3 folds) in the level of miR-145 was sufficient to reduce the 
level of SOX2 protein in human NSCs. Thus, miR-145 likely fine-tunes the level of 
SOX2 in NSCs to control the balance between self-renewal and differentiation, which 
ties in well with the dose-dependent function of SOX2 (Kopp et al., 2008; Pevny and 
Nicolis, 2010).  
In this study we noted that the repression of SOX2 protein by miR-145 was without 
detectable changes in SOX2 transcript levels, indicating that miR-145 mediated 
direct translational repression of SOX2 in NSCs (Bartel, 2004). In contrast, Xu et al. 
(2009) showed that in hESCs miR-145 repressed SOX2 at the mRNA level, likely by 
mRNA cleavage or destabilization, rather than at the protein level (Appendix Figure 
A3). Whether such a change in the mechanism of post-transcriptional silencing by a 
miRNA has implications about the developmental state of a cell and what caused this 
change are questions that remain unanswered. Notably, besides SOX2 protein levels, 
SOX2 mRNA levels were also downregulated during the differentiation from NSC to 
GPC (Figure 3.7) which reveals that the SOX2-silencing action of miR-145 per se 
does not account fully for the downregulation in SOX2 expression. The repression of 
SOX2 at the mRNA level may be due to the effect of other miRNAs or due to 
regulation at the transcriptional level involving activated transcriptional repressors or 
inhibited transcriptional enhancers/activators of the SOX2 gene. Nonetheless, our 
study herein is a start towards uncovering the function of miRNAs in regulating the 
balance between NSC self-renewal and differentiation as well as the switch between 
neurogenesis and gliogenesis in humans. 
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Interestingly, all the four miRNAs that were identified to be upregulated during GPC 
differentiation have been implicated in cancer. Both miR-21 and -221 have been 
associated with tumorigenesis and cancer progression, and are termed ‘oncomirs’. 
miR-21 and miR-221 are typically found to be overexpressed in several tumor tissues 
and cancer cell lines (Gao et al., 2011; Pineau et al., 2010; Zheng et al., 2011). In 
particular, miR-21 is highly expressed in squamous cell lung carcinoma (Gao et al., 
2011) and breast cancer tissue (Si et al., 2007), and likely contribute to tumor 
progression by downregulating tumor suppressor genes (Zhu et al., 2007). miR-221 
has been found to be upregulated in estrogen receptor -negative breast tumors, 
hepatocellular carcinoma and prostate cancers (Li et al., 2011; Pineau et al., 2010; 
Zheng et al., 2011) and confers drug resistance to breast cancer cells (Rao et al., 
2011; Zhao et al., 2008). In contrast, miR-22 and miR-145 reportedly perform tumor 
suppressor functions (Spizzo et al., 2010; Xu et al., 2011) and are frequently 
downregulated in various cancer cells (Akao et al., 2007; Zhang et al., 2010a), 
including glioma U87 cells (Appendix Figure A1). Understanding the role of these 
miRNAs in cancer and in GPCs may bear significance in glioma as several studies 
have conjectured that aberrant GPCs are a possible source of glioma-initiating cells 
(Canoll and Goldman, 2008; Lei et al., 2011; Sugiarto et al., 2011; Walton et al., 
2009). In line with our findings, Fang et al. (2011) proposed that miR-145 may be 
dysregulated in aberrant GPCs leading to increased expression of SOX2, which is a 
trait of several types of gliomas including glioblastoma multiforme (GBM) (Schmitz et 
al., 2007), and eventually to neoplastic transformations (Fang et al., 2011). Hence, 
miRNAs, such as miR-145, could potentially be used as therapeutics to treat gliomas. 
A problem faced in cell-based regenerative therapy of CNS injury or disease is that 
endogenous GPCs and transplanted NSCs or GPCs at the site of injury in the CNS 
are found to preferentially differentiate into astrocytes which contribute to the 
proteoglycan-rich astrocytic scar that inhibits neuronal regrowth (Parr et al., 2008; 
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Tatsumi et al., 2008). Hence, our attempt to understand the miRNA-mediated 
regulatory mechanisms governing the change from NSCs to GPCs could be useful in 
this aspect to reduce contributions of transplanted NSCs to the astrocytic scar and 
coax them towards neurogenic repair. However, further studies are still required to 
fully understand how the interplay between transcription factors, like PAX6 and SOX2, 
and the miRNAs we have identified in NSCs control the shift from self-renewal to 
gliogenesis, away from neurogenesis. 
 
4.3.1 Future work 
While we have shown miR-22 and miR-221 to be able to target the PAX6 3’ UTR, we 
have yet to show conclusively that they are able to repress PAX6 expression. Our 
findings have shown that baculoviruses are effective for introducing transgene 
expression in NSCs and could be used to induce ectopic expression of miRNAs for 
gain-of-function studies or induce expression of miRNA inhibitors for loss-of-function 
studies. Thus, the next step would be to create baculoviral vectors expressing miR-
22 or miR-221 and their respective inhibitors for such studies to validate that PAX6 is 
a bona fide target in NSCs, and further, to evaluate the potential roles of miR-22 and 
miR-221 as regulators of the switch from neurogenesis to gliogenesis. 
Our findings that post-transcriptional regulation by miR-145 plays an important role in 
regulating SOX2 levels in NSCs suggest that miR-145 may function as a crucial 
effector of the shift from NSC self-renewal to differentiation. This necessitates 
additional experiments to examine the physiological effects of upregulating or 
inhibiting miR-145 in NSCs and to elucidate whether miR-145 drives the 
differentiation of NSCs. Such investigations would allow us to distinguish whether the 
increase in miR-145 levels is a cause, consequence or just an epiphenomenon of 
GPC differentiation. Interestingly, it has been elucidated that miR-145 and SOX2 
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form a double-negative feedback loop in hESCs and GBM cells (Fang et al., 2011; 
Xu et al., 2009); whether this regulatory loop exists in NSCs or GPCs remains to be 
examined. 
Additionally, it may be worthwhile to investigate the SOX2-targeting ability of the 
other miRNAs that we have identified to be upregulated and to possess predicted 
binding sites in SOX2 mRNA. This includes miR-21 which, in mouse, has been found 
to negatively regulate the expression of Sox2 in ESCs (Singh et al., 2008), along with 
other pluripotency genes such as Nanog, c-myc and Oct4, even though, in human, 
miR-21 displays a positive correlation with SOX2 with both having upregulated 
expression in gliomas (Polajeva et al., 2012). Our study alludes to the possibility of a 
set of miRNAs governing the fate decision of the human NSC and such a discovery 
could open new avenues to examine the neurogenic to gliogenic switch in human 
brain development and to utilize miRNAs as targets, or as a stepping stone to identify 
other targets, to expedite the process of neural differentiation and obtain desired cell 
types for cell-based regenerative medicine. Thus, it warrants further investigation into 




Chapter 5: Summary and conclusion 
NSCs have shown great promise for therapeutic applications in regenerative 
medicine. However, despite advancements in methods to derive, expand and 
differentiate NSCs, obtaining expandable pure NSC populations and specific 
neuronal cell types remain major challenges for therapeutic applications. Developing 
a greater understanding of NSC self-renewal and cell lineage specification will be 
invaluable for the generation and characterization of NSCs and diverse neural 
progenies for cell therapy. Hence, this study was carried out to uncover and 
understand the miRNA regulatory mechanisms involved in the differentiation of 
human NSCs into lineage-restricted progeny. 
To this end, we derived NSCs from hESCs via a neurosphere culture and a neural 
rosette adherent culture (Reubinoff et al., 2001; Swistowski et al., 2009). Both 
methods yielded NSC populations expressing the fundamental neuroectodermal 
markers, including SOX2, PAX6, SOX1 and Nestin, but displayed some degree of 
heterogeneity in terms of NSC and GPC marker expression, a trait common to most 
if not all methods of NSC culture, thus highlighting the current problem of deriving 
and maintaining ‘pure’ populations of NSCs. Nevertheless, through a simple 
approach of exposure to PDGF-AA and bFGF, these hESC-derived NSCs could give 
rise to relatively pure populations of NG2+ cells that also bear other characteristic 
GPC markers such as PDGFR and A2B5. We further demonstrated the functional 
application of GPCs for cancer therapy using eGFP-expressing hESC-derived GPCs. 
Our study demonstrates for the first time the in vitro glioma-migratory potential of 
hESC-derived GPCs and, consequently, calls for further investigation to determine 
the in vivo tumor-targeting ability of GPCs. 
With robust methods to generate NSCs and GPCs from hESCs, we proceeded to 
study the transition from NSC to GPC. Using a miRNA microarray and quantitative 
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PCR analysis to compare the miRNA expression profiles of NSCs and early GPCs, 
we have identified four miNAs, miR-21, 22, 221 and 145, that were upregulated in 
GPCs within the first week of differentiation from NSCs. According to bioinformatics 
analysis, these four miRNAs were predicted to target both PAX6 and SOX2. miR-22 
and miR-221 were able to target the 3’ UTR of PAX6. Although unable to verify these 
results in NSCs due to poor transfection efficiencies, our preliminary findings, 
coupled with previous findings that PAX6 is a key neurogenic factor, suggest that 
miR-22 or miR-221 may regulate the switch from neuronal to glial fate during NSC 
differentiation by targeting PAX6 and warrant further investigation (Kallur et al., 2008; 
Mo and Zecevic, 2008; Philips et al., 2005; Zhang et al., 2010c). 
We subsequently demonstrated that baculoviral vectors could be used for efficient 
gene delivery into NSCs and circumvent the low efficiency of transfection of human 
NSCs. Hence, using baculoviral vectors to induce upregulation of miR-145 or deliver 
miR-145 inhibitors into NSCs, we were able to elucidate that miR-145 represses 
SOX2 in NSCs. This miR-145-mediated repression of SOX2 was observed in both 
hESC-derived NSCs and ReNcell NSCs, and may likely be a phenomenon that 
occurs in all human NSCs during differentiation. Our findings from this study extend 
upon previous reports that miR-145 negatively regulates SOX2 in hESCs and GBM 
cells (Fang et al., 2011; Xu et al., 2009), and suggest that miR-145 could possibly 
regulate the transition from multipotency to a more restricted fate in NSCs through 
the formation of a negative feedback loop with SOX2. Considering that there are 
predicted target sites in SOX2 mRNA for miR-21, 22 and 221, these other 
upregulated miRNAs may also be involved in the negative regulation of SOX2 and 
modulate NSC differentiation. 
Therefore, our study presents incipient evidence that miRNAs function as regulators 
of self-renewal and fate specification in human NSCs by acting on key fate 
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determining transcription factors such as PAX6 and SOX2, and demonstrates the 
feasibility of hESC-derived NSCs as a model to uncover molecular players 
underpinning neuro-development in human. We conjecture that miRNAs and their 
inhibitors may prove to be useful agents to ‘freeze’ NSCs in a multipotent state or 
direct their differentiation into desired progeny. Thus, we advocate further 
investigation into the role of miRNAs in regulating the switch between neurogenesis 
and gliogenesis in human NSCs which ultimately would advance our understanding 
of the underlying teleology of the molecular events that occur in the NSC at each 
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NS GPC 7-days post-diff Hela U87
Appendix Figure A1 Relative endogenous expression levels of miR-145, -21, -22 and 
-221 in HeLa and U87 cells. Real-time qPCR analysis of miR-22, -21, -221 and -145 
expression in hESC-derived neurosphere NSCs (NS), GPCs 7 days post-differentiation 
from hESC-derived neurosphere NSCs, HeLa and U87. Values in ( ) represent relative 
fold decrease in expression normalized to 5S rRNA and expressed relative to GPC. Data 
represents mean + SD of triplicates. 
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Appendix Figure A2 Validation of miR-145 targeting of the OCT4, SOX2, and KLF4 3′ 
UTRs. Luciferase reporter assay where HeLa cells were transfected with luciferase 
reporter constructs, which carry wildtype (WT) or mutant 3’ UTRs of OCT4, SOX2 and 
KLF4, along with miR-145 precursor mimics. Mutant UTRs have a 6 bp deletion in the 
miR-145 target site. miR-145 specifically represses its targets. Image is from Figure 1 of 
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Appendix Figure A3 Effect of miR-145 on endogenous OCT4, KLF4, and SOX2 in 
hESCs. (B–C) Relative mRNA (B) and protein (C) levels of OCT4, SOX2, and KLF4 in 
control Lenti-scr or Lenti-miR-145 transduced hESCs. (E–F) Relative mRNA (E) and 
protein (F) levels of OCT4, SOX2, and KLF4 in LNA-scr or LNA-miR-145 transfected 
hESCs. In real-time RT-PCR, GAPDH mRNA is the normalization control (B and E). In 
western blot (C and F), protein level quantification was normalized to GAPDH. Image is 









Appendix Figure A4 Effect of miR-21, -22, -221 and -145 on PAX6 and SOX2 
expression in ReNcell NSCs. Western blot analysis of PAX6 and SOX2 in ReNcell 
NSCs 72 hours after transfection with miR-21, miR-22, miR-221, miR-145, or negative 
control mimics. Densitometry was performed using ImageJ software and protein amounts 
are normalized to β-actin loading control and presented relative to miRNA mimic negative 
control 2. 
